EU-1-04-273,https://www.ema.europa.eu/documents/scientific-discussion/lysodren-epar-scientific-discussion_en.pdf
EU-1-04-274,https://www.ema.europa.eu/documents/scientific-discussion/velcade-epar-scientific-discussion_en.pdf
EU-1-04-275,https://www.ema.europa.eu/documents/scientific-discussion/litak-epar-scientific-discussion_en.pdf
EU-1-98-091,https://www.ema.europa.eu/documents/scientific-discussion/kinzalmono-epar-scientific-discussion_en.pdf
EU-1-04-278,https://www.ema.europa.eu/documents/scientific-discussion/levemir-epar-scientific-discussion_en.pdf
EU-1-04-276,https://www.ema.europa.eu/documents/scientific-discussion/abilify-epar-scientific-discussion_en.pdf
EU-1-04-277,https://www.ema.europa.eu/documents/scientific-discussion/tachosil-epar-scientific-discussion_en.pdf
EU-1-04-281,https://www.ema.europa.eu/documents/scientific-discussion/erbitux-epar-scientific-discussion_en.pdf
EU-1-04-282,https://www.ema.europa.eu/documents/scientific-discussion/telzir-epar-scientific-discussion_en.pdf
EU-1-04-279,https://www.ema.europa.eu/documents/scientific-discussion/lyrica-epar-scientific-discussion_en.pdf
EU-1-04-280,https://www.ema.europa.eu/documents/scientific-discussion/yentreve-epar-scientific-discussion_en.pdf
EU-1-04-284,https://www.ema.europa.eu/documents/scientific-discussion/pedea-epar-scientific-discussion_en.pdf
EU-1-04-285,https://www.ema.europa.eu/documents/scientific-discussion/apidra-epar-scientific-discussion_en.pdf
EU-1-04-286,https://www.ema.europa.eu/documents/scientific-discussion/wilzin-epar-scientific-discussion_en.pdf
EU-1-04-290,https://www.ema.europa.eu/documents/scientific-discussion/alimta-epar-scientific-discussion_en.pdf
EU-1-04-292,https://www.ema.europa.eu/documents/scientific-discussion/mimpara-epar-scientific-discussion_en.pdf
EU-1-04-294,https://www.ema.europa.eu/documents/scientific-discussion/emselex-epar-scientific-discussion_en.pdf
EU-1-04-295,https://www.ema.europa.eu/documents/scientific-discussion/xagrid-epar-scientific-discussion_en.pdf
EU-1-04-296,https://www.ema.europa.eu/documents/scientific-discussion/cymbalta-epar-scientific-discussion_en.pdf
EU-1-04-298,https://www.ema.europa.eu/documents/scientific-discussion/kivexa-epar-scientific-discussion_en.pdf
EU-1-04-299,https://www.ema.europa.eu/documents/scientific-discussion/fendrix-epar-scientific-discussion_en.pdf
EU-1-04-300,https://www.ema.europa.eu/documents/scientific-discussion/avastin-epar-scientific-discussion_en.pdf
EU-1-04-302,https://www.ema.europa.eu/documents/scientific-discussion/prialt-epar-scientific-discussion_en.pdf
EU-1-04-303,https://www.ema.europa.eu/documents/scientific-discussion/orfadin-epar-scientific-discussion_en.pdf
EU-1-04-305,https://www.ema.europa.eu/documents/scientific-discussion/truvada-epar-scientific-discussion_en.pdf
EU-1-04-304,https://www.ema.europa.eu/documents/scientific-discussion/azilect-epar-scientific-discussion_en.pdf
EU-1-04-306,https://www.ema.europa.eu/documents/scientific-discussion/aloxi-epar-scientific-discussion_en.pdf
EU-1-04-307,https://www.ema.europa.eu/documents/scientific-discussion/zonegran-epar-scientific-discussion_en.pdf
EU-1-05-308,https://www.ema.europa.eu/documents/scientific-discussion/aclasta-epar-scientific-discussion_en.pdf
EU-1-05-310,https://www.ema.europa.eu/documents/scientific-discussion/fosavance-epar-scientific-discussion_en.pdf
EU-1-05-311,https://www.ema.europa.eu/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf
EU-1-05-312,https://www.ema.europa.eu/documents/scientific-discussion/xyrem-epar-scientific-discussion_en.pdf
EU-1-05-315,https://www.ema.europa.eu/documents/scientific-discussion/aptivus-epar-scientific-discussion_en.pdf
EU-1-05-316,https://www.ema.europa.eu/documents/scientific-discussion/procoralan-epar-scientific-discussion_en.pdf
EU-1-05-317,https://www.ema.europa.eu/documents/scientific-discussion/corlentor-epar-scientific-discussion_en.pdf
EU-1-05-320,https://www.ema.europa.eu/documents/scientific-discussion/noxafil-epar-scientific-discussion_en.pdf
EU-1-05-319,https://www.ema.europa.eu/documents/scientific-discussion/xolair-epar-scientific-discussion_en.pdf
EU-1-05-318,https://www.ema.europa.eu/documents/scientific-discussion/revatio-epar-scientific-discussion_en.pdf
EU-1-05-322,https://www.ema.europa.eu/documents/scientific-discussion/yttriga-epar-scientific-discussion_en.pdf
EU-1-05-323,https://www.ema.europa.eu/documents/scientific-discussion/proquad-epar-scientific-discussion_en.pdf
EU-1-05-324,https://www.ema.europa.eu/documents/scientific-discussion/naglazyme-epar-scientific-discussion_en.pdf
EU-1-05-328,https://www.ema.europa.eu/documents/scientific-discussion/cubicin-epar-scientific-discussion_en.pdf
EU-1-05-329,https://www.ema.europa.eu/documents/scientific-discussion/kiovig-epar-scientific-discussion_en.pdf
EU-1-05-330,https://www.ema.europa.eu/documents/scientific-discussion/rotarix-epar-scientific-discussion_en.pdf
EU-1-05-331,https://www.ema.europa.eu/documents/scientific-discussion/neupro-epar-scientific-discussion_en.pdf
EU-1-06-332,https://www.ema.europa.eu/documents/scientific-discussion/omnitrope-epar-scientific-discussion_en.pdf
EU-1-06-333,https://www.ema.europa.eu/documents/scientific-discussion/myozyme-epar-scientific-discussion_en.pdf
EU-1-06-336,https://www.ema.europa.eu/documents/scientific-discussion/tygacil-epar-scientific-discussion_en.pdf
EU-1-06-337,https://www.ema.europa.eu/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf
EU-1-06-334,https://www.ema.europa.eu/documents/scientific-discussion/evoltra-epar-scientific-discussion_en.pdf
EU-1-06-338,https://www.ema.europa.eu/documents/scientific-discussion/duotrav-epar-scientific-discussion_en.pdf
EU-1-06-340,https://www.ema.europa.eu/documents/scientific-discussion/ganfort-epar-scientific-discussion_en.pdf
EU-1-06-341,https://www.ema.europa.eu/documents/scientific-discussion/zostavax-epar-scientific-discussion_en.pdf
EU-1-06-342,https://www.ema.europa.eu/documents/scientific-discussion/nexavar-epar-scientific-discussion_en.pdf
EU-1-06-346,https://www.ema.europa.eu/documents/scientific-discussion/tysabri-epar-scientific-discussion_en.pdf
EU-1-06-347,https://www.ema.europa.eu/documents/scientific-discussion/sutent-epar-scientific-discussion_en.pdf
EU-1-06-343,https://www.ema.europa.eu/documents/scientific-discussion/baraclude-epar-scientific-discussion_en.pdf
EU-1-06-348,https://www.ema.europa.eu/documents/scientific-discussion/rotateq-epar-scientific-discussion_en.pdf
EU-1-06-350,https://www.ema.europa.eu/documents/scientific-discussion/savene-epar-scientific-discussion_en.pdf
EU-1-06-354,https://www.ema.europa.eu/documents/scientific-discussion/competact-epar-scientific-discussion_en.pdf
EU-1-06-356,https://www.ema.europa.eu/documents/scientific-discussion/exjade-epar-scientific-discussion_en.pdf
EU-1-06-357,https://www.ema.europa.eu/documents/scientific-discussion/gardasil-epar-scientific-discussion_en.pdf
EU-1-06-359,https://www.ema.europa.eu/documents/scientific-discussion/suboxone-epar-scientific-discussion_en.pdf
EU-1-06-360,https://www.ema.europa.eu/documents/scientific-discussion/champix-epar-scientific-discussion_en.pdf
EU-1-06-361,https://www.ema.europa.eu/documents/scientific-discussion/luminity-epar-scientific-discussion_en.pdf
EU-1-06-362,https://www.ema.europa.eu/documents/scientific-discussion/byetta-epar-scientific-discussion_en.pdf
EU-1-06-363,https://www.ema.europa.eu/documents/scientific-discussion/sprycel-epar-scientific-discussion_en.pdf
EU-1-06-367,https://www.ema.europa.eu/documents/scientific-discussion/diacomit-epar-scientific-discussion_en.pdf
EU-1-06-364,https://www.ema.europa.eu/documents/scientific-discussion/adrovance-epar-scientific-discussion_en.pdf
EU-1-06-365,https://www.ema.europa.eu/documents/scientific-discussion/elaprase-epar-scientific-discussion_en.pdf
EU-1-06-366,https://www.ema.europa.eu/documents/scientific-discussion/tandemact-epar-scientific-discussion_en.pdf
EU-1-06-378,https://www.ema.europa.eu/documents/scientific-discussion/inovelon-epar-scientific-discussion_en.pdf
EU-1-06-376,https://www.ema.europa.eu/documents/scientific-discussion/irbesartan-winthrop-epar-scientific-discussion_en.pdf
EU-1-06-370,https://www.ema.europa.eu/documents/procedural-steps/exforge-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-06-372,https://www.ema.europa.eu/documents/scientific-discussion/copalia-epar-scientific-discussion_en.pdf
EU-1-06-371,https://www.ema.europa.eu/documents/scientific-discussion/dafiro-epar-scientific-discussion_en.pdf
EU-1-06-374,https://www.ema.europa.eu/documents/scientific-discussion/lucentis-epar-scientific-discussion_en.pdf
EU-1-06-377,https://www.ema.europa.eu/documents/scientific-discussion/irbesartan-hydrochlorothiazide-winthrop-epar-scientific-discussion_en.pdf
EU-1-06-380,https://www.ema.europa.eu/documents/scientific-discussion/prezista-epar-scientific-discussion_en.pdf
EU-1-06-379,https://www.ema.europa.eu/documents/scientific-discussion/cystadane-epar-scientific-discussion_en.pdf
EU-1-07-382,https://www.ema.europa.eu/documents/scientific-discussion/xelevia-epar-scientific-discussion_en.pdf
EU-1-07-383,https://www.ema.europa.eu/documents/scientific-discussion/januvia-epar-scientific-discussion_en.pdf
EU-1-07-387,https://www.ema.europa.eu/documents/scientific-discussion/advagraf-epar-scientific-discussion_en.pdf
EU-1-07-386,https://www.ema.europa.eu/documents/scientific-discussion/toviaz-epar-scientific-discussion_en.pdf
EU-1-07-389,https://www.ema.europa.eu/documents/scientific-discussion/orencia-epar-scientific-discussion_en.pdf
EU-1-07-391,https://www.ema.europa.eu/documents/scientific-discussion/revlimid-epar-scientific-discussion_en.pdf
EU-1-07-392,https://www.ema.europa.eu/documents/scientific-discussion/circadin-epar-scientific-discussion_en.pdf
EU-1-07-393,https://www.ema.europa.eu/documents/scientific-discussion/soliris-epar-scientific-discussion_en.pdf
EU-1-07-396,https://www.ema.europa.eu/documents/scientific-discussion/pergoveris-epar-scientific-discussion_en.pdf
EU-1-07-395,https://www.ema.europa.eu/documents/scientific-discussion/invega-epar-scientific-discussion_en.pdf
EU-1-07-397,https://www.ema.europa.eu/documents/scientific-discussion/siklos-epar-scientific-discussion_en.pdf
EU-1-07-400,https://www.ema.europa.eu/documents/procedural-steps/mircera-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-07-399,https://www.ema.europa.eu/documents/scientific-discussion/aerinaze-epar-scientific-discussion_en.pdf
EU-1-07-401,https://www.ema.europa.eu/documents/scientific-discussion/alli-epar-scientific-discussion_en.pdf
EU-1-07-402,https://www.ema.europa.eu/documents/scientific-discussion/increlex-epar-scientific-discussion_en.pdf
EU-1-07-403,https://www.ema.europa.eu/documents/scientific-discussion/atriance-epar-scientific-discussion_en.pdf
EU-1-07-404,https://www.ema.europa.eu/documents/procedural-steps/flebogammadif-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-07-412,https://www.ema.europa.eu/documents/scientific-discussion/abseamed-epar-scientific-discussion_en.pdf
EU-1-07-405,https://www.ema.europa.eu/documents/scientific-discussion/rasilez-epar-scientific-discussion_en.pdf
EU-1-07-410,https://www.ema.europa.eu/documents/scientific-discussion/binocrit-epar-scientific-discussion_en.pdf
EU-1-07-411,https://www.ema.europa.eu/documents/scientific-discussion/epoetin-alfa-hexal-epar-scientific-discussion_en.pdf
EU-1-07-413,https://www.ema.europa.eu/documents/scientific-discussion/gliolan-epar-scientific-discussion_en.pdf
EU-1-07-414,https://www.ema.europa.eu/documents/scientific-discussion/galvus-epar-scientific-discussion_en.pdf
EU-1-07-415,https://www.ema.europa.eu/documents/scientific-discussion/zalasta-epar-scientific-discussion_en.pdf
EU-1-07-416,https://www.ema.europa.eu/documents/scientific-discussion/ecalta-epar-scientific-discussion_en.pdf
EU-1-07-417,https://www.ema.europa.eu/documents/scientific-discussion/yondelis-epar-scientific-discussion_en.pdf
EU-1-07-418,https://www.ema.europa.eu/documents/scientific-discussion/celsentri-epar-scientific-discussion_en.pdf
EU-1-07-419,https://www.ema.europa.eu/documents/scientific-discussion/cervarix-epar-scientific-discussion_en.pdf
EU-1-07-424,https://www.ema.europa.eu/documents/scientific-discussion/torisel-epar-scientific-discussion_en.pdf
EU-1-07-420,https://www.ema.europa.eu/documents/procedural-steps/cyanokit-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-07-425,https://www.ema.europa.eu/documents/scientific-discussion/eucreas-epar-scientific-discussion_en.pdf
EU-1-07-422,https://www.ema.europa.eu/documents/scientific-discussion/tasigna-epar-scientific-discussion_en.pdf
EU-1-07-423,https://www.ema.europa.eu/documents/scientific-discussion/vectibix-epar-scientific-discussion_en.pdf
EU-1-07-427,https://www.ema.europa.eu/documents/scientific-discussion/olanzapine-teva-epar-scientific-discussion_en.pdf
EU-1-07-431,https://www.ema.europa.eu/documents/scientific-discussion/retacrit-epar-scientific-discussion_en.pdf
EU-1-07-432,https://www.ema.europa.eu/documents/scientific-discussion/silapo-epar-scientific-discussion_en.pdf
EU-1-07-433,https://www.ema.europa.eu/documents/scientific-discussion/nevanac-epar-scientific-discussion_en.pdf
EU-1-07-428,https://www.ema.europa.eu/documents/assessment-report/abraxane-epar-public-assessment-report_en.pdf
EU-1-07-434,https://www.ema.europa.eu/documents/scientific-discussion/avamys-epar-scientific-discussion_en.pdf
EU-1-07-436,https://www.ema.europa.eu/documents/scientific-discussion/isentress-epar-scientific-discussion_en.pdf
EU-1-07-438,https://www.ema.europa.eu/documents/assessment-report/myfenax-epar-public-assessment-report_en.pdf
EU-1-07-439,https://www.ema.europa.eu/documents/assessment-report/mycophenolate-mofetil-teva-epar-public-assessment-report_en.pdf
EU-1-07-440,https://www.ema.europa.eu/documents/assessment-report/tyverb-epar-public-assessment-report_en.pdf
EU-1-08-441,https://www.ema.europa.eu/documents/scientific-discussion/effentora-epar-scientific-discussion_en.pdf
EU-1-08-442,https://www.ema.europa.eu/documents/assessment-report/pradaxa-epar-public-assessment-report_en.pdf
EU-1-08-446,https://www.ema.europa.eu/documents/assessment-report/privigen-epar-public-assessment-report_en.pdf
EU-1-08-447,https://www.ema.europa.eu/documents/assessment-report/adenuric-epar-public-assessment-report_en.pdf
EU-1-95-003,https://www.ema.europa.eu/documents/scientific-discussion/betaferon-epar-scientific-discussion_en.pdf
EU-1-95-002,https://www.ema.europa.eu/documents/scientific-discussion/taxotere-epar-scientific-discussion_en.pdf
EU-1-96-005,https://www.ema.europa.eu/documents/scientific-discussion/cellcept-epar-scientific-discussion_en.pdf
EU-1-96-004,https://www.ema.europa.eu/documents/scientific-discussion/fareston-epar-scientific-discussion_en.pdf
EU-1-96-006,https://www.ema.europa.eu/documents/scientific-discussion/novoseven-epar-scientific-discussion_en.pdf
EU-1-96-007,https://www.ema.europa.eu/documents/scientific-discussion/humalog-epar-scientific-discussion_en.pdf
EU-1-96-008,https://www.ema.europa.eu/documents/scientific-discussion/puregon-epar-scientific-discussion_en.pdf
EU-1-96-012,https://www.ema.europa.eu/documents/scientific-discussion/bondronat-epar-scientific-discussion_en.pdf
EU-1-97-033,https://www.ema.europa.eu/documents/scientific-discussion/avonex-epar-scientific-discussion_en.pdf
EU-1-96-018,https://www.ema.europa.eu/documents/scientific-discussion/rapilysin-epar-scientific-discussion_en.pdf
EU-1-96-010,https://www.ema.europa.eu/documents/scientific-discussion/rilutek-epar-scientific-discussion_en.pdf
EU-1-96-020,https://www.ema.europa.eu/documents/scientific-discussion/twinrix-adult-epar-scientific-discussion_en.pdf
EU-1-96-022,https://www.ema.europa.eu/documents/scientific-discussion/zyprexa-epar-scientific-discussion_en.pdf
EU-1-97-031,https://www.ema.europa.eu/documents/scientific-discussion/neorecormon-epar-scientific-discussion_en.pdf
EU-1-96-027,https://www.ema.europa.eu/documents/scientific-discussion/hycamtin-epar-scientific-discussion_en.pdf
EU-1-96-015,https://www.ema.europa.eu/documents/scientific-discussion/epivir-epar-scientific-discussion_en.pdf
EU-1-96-016,https://www.ema.europa.eu/documents/scientific-discussion/norvir-epar-scientific-discussion_en.pdf
EU-1-97-029,https://www.ema.europa.eu/documents/scientific-discussion/twinrix-paediatric-epar-scientific-discussion_en.pdf
EU-1-97-044,https://www.ema.europa.eu/documents/scientific-discussion/tasmar-epar-scientific-discussion_en.pdf
EU-1-97-039,https://www.ema.europa.eu/documents/scientific-discussion/cystagon-epar-scientific-discussion_en.pdf
EU-1-97-045,https://www.ema.europa.eu/documents/scientific-discussion/helicobacter-test-infai-epar-scientific-discussion_en.pdf
EU-1-97-046,https://www.ema.europa.eu/documents/scientific-discussion/aprovel-epar-scientific-discussion_en.pdf
EU-1-97-047,https://www.ema.europa.eu/documents/scientific-discussion/benefix-epar-scientific-discussion_en.pdf
EU-1-97-049,https://www.ema.europa.eu/documents/scientific-discussion/karvea-epar-scientific-discussion_en.pdf
EU-1-97-051,https://www.ema.europa.eu/documents/scientific-discussion/mirapexin-epar-scientific-discussion_en.pdf
EU-1-97-050,https://www.ema.europa.eu/documents/scientific-discussion/sifrol-epar-scientific-discussion_en.pdf
EU-1-97-053,https://www.ema.europa.eu/documents/scientific-discussion/cerezyme-epar-scientific-discussion_en.pdf
EU-1-97-057,https://www.ema.europa.eu/documents/scientific-discussion/quadramet-epar-scientific-discussion_en.pdf
EU-1-97-055,https://www.ema.europa.eu/documents/scientific-discussion/viramune-epar-scientific-discussion_en.pdf
EU-1-98-058,https://www.ema.europa.eu/documents/scientific-discussion/combivir-epar-scientific-discussion_en.pdf
EU-1-98-064,https://www.ema.europa.eu/documents/scientific-discussion/pylobactell-epar-scientific-discussion_en.pdf
EU-1-98-063,https://www.ema.europa.eu/documents/scientific-discussion/rebif-epar-scientific-discussion_en.pdf
EU-1-98-067,https://www.ema.europa.eu/documents/scientific-discussion/mabthera-epar-scientific-discussion_en.pdf
EU-1-98-065,https://www.ema.europa.eu/documents/procedural-steps/optison-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-98-066,https://www.ema.europa.eu/documents/scientific-discussion/exelon-epar-scientific-discussion_en.pdf
EU-1-98-069,https://www.ema.europa.eu/documents/scientific-discussion/plavix-epar-scientific-discussion_en.pdf
EU-1-98-070,https://www.ema.europa.eu/documents/scientific-discussion/iscover-epar-scientific-discussion_en.pdf
EU-1-98-071,https://www.ema.europa.eu/documents/scientific-discussion/xenical-epar-scientific-discussion_en.pdf
EU-1-98-076,https://www.ema.europa.eu/documents/scientific-discussion/novonorm-epar-scientific-discussion_en.pdf
EU-1-98-073,https://www.ema.europa.eu/documents/scientific-discussion/evista-epar-scientific-discussion_en.pdf
EU-1-98-074,https://www.ema.europa.eu/documents/scientific-discussion/optruma-epar-scientific-discussion_en.pdf
EU-1-98-077,https://www.ema.europa.eu/documents/scientific-discussion/viagra-epar-scientific-discussion_en.pdf
EU-1-98-080,https://www.ema.europa.eu/documents/scientific-discussion/aldara-epar-scientific-discussion_en.pdf
EU-1-98-081,https://www.ema.europa.eu/documents/scientific-discussion/comtan-epar-scientific-discussion_en.pdf
EU-1-98-082,https://www.ema.europa.eu/documents/scientific-discussion/comtess-epar-scientific-discussion_en.pdf
EU-1-98-084,https://www.ema.europa.eu/documents/scientific-discussion/simulect-epar-scientific-discussion_en.pdf
EU-1-98-086,https://www.ema.europa.eu/documents/scientific-discussion/coaprovel-epar-scientific-discussion_en.pdf
EU-1-98-085,https://www.ema.europa.eu/documents/scientific-discussion/karvezide-epar-scientific-discussion_en.pdf
EU-1-97-030,https://www.ema.europa.eu/documents/scientific-discussion/insuman-epar-scientific-discussion_en.pdf
EU-1-98-092,https://www.ema.europa.eu/documents/scientific-discussion/prometax-epar-scientific-discussion_en.pdf
EU-1-98-089,https://www.ema.europa.eu/documents/scientific-discussion/pritor-epar-scientific-discussion_en.pdf
EU-1-98-090,https://www.ema.europa.eu/documents/scientific-discussion/micardis-epar-scientific-discussion_en.pdf
EU-1-98-096,https://www.ema.europa.eu/documents/scientific-discussion/temodal-epar-scientific-discussion_en.pdf
EU-1-98-095,https://www.ema.europa.eu/documents/scientific-discussion/emadine-epar-scientific-discussion_en.pdf
EU-1-99-097,https://www.ema.europa.eu/documents/scientific-discussion/beromun-epar-scientific-discussion_en-0.pdf
EU-1-99-100,https://www.ema.europa.eu/documents/scientific-discussion/cetrotide-epar-scientific-discussion_en.pdf
EU-1-99-103,https://www.ema.europa.eu/documents/scientific-discussion/refacto-af-epar-scientific-discussion_en.pdf
EU-1-99-107,https://www.ema.europa.eu/documents/scientific-discussion/rebetol-epar-scientific-discussion_en.pdf
EU-1-99-108,https://www.ema.europa.eu/documents/scientific-discussion/ferriprox-epar-scientific-discussion_en.pdf
EU-1-96-026,https://www.ema.europa.eu/documents/scientific-discussion/invirase-epar-scientific-discussion_en.pdf
EU-1-99-110,https://www.ema.europa.eu/documents/scientific-discussion/sustiva-epar-scientific-discussion_en.pdf
EU-1-99-111,https://www.ema.europa.eu/documents/scientific-discussion/stocrin-epar-scientific-discussion_en.pdf
EU-1-99-109,https://www.ema.europa.eu/documents/scientific-discussion/integrilin-epar-scientific-discussion_en.pdf
EU-1-99-112,https://www.ema.europa.eu/documents/scientific-discussion/ziagen-epar-scientific-discussion_en.pdf
EU-1-99-114,https://www.ema.europa.eu/documents/scientific-discussion/zeffix-epar-scientific-discussion_en.pdf
EU-1-99-116,https://www.ema.europa.eu/documents/scientific-discussion/remicade-epar-scientific-discussion_en.pdf
EU-1-99-119,https://www.ema.europa.eu/documents/scientific-discussion/novorapid-epar-scientific-discussion_en.pdf
EU-1-99-117,https://www.ema.europa.eu/documents/scientific-discussion/synagis-epar-scientific-discussion_en.pdf
EU-1-99-118,https://www.ema.europa.eu/documents/scientific-discussion/arava-epar-scientific-discussion_en.pdf
EU-1-99-120,https://www.ema.europa.eu/documents/scientific-discussion/ammonaps-epar-scientific-discussion_en.pdf
EU-1-99-122,https://www.ema.europa.eu/documents/scientific-discussion/thyrogen-epar-scientific-discussion_en.pdf
EU-1-99-123,https://www.ema.europa.eu/documents/scientific-discussion/renagel-epar-scientific-discussion_en.pdf
EU-1-99-124,https://www.ema.europa.eu/documents/scientific-discussion/tractocile-epar-scientific-discussion_en.pdf
EU-1-99-125,https://www.ema.europa.eu/documents/scientific-discussion/zyprexa-velotab-epar-scientific-discussion_en.pdf
EU-1-99-126,https://www.ema.europa.eu/documents/scientific-discussion/enbrel-epar-scientific-discussion_en.pdf
EU-1-00-129,https://www.ema.europa.eu/documents/scientific-discussion/azopt-epar-scientific-discussion_en.pdf
EU-1-00-130,https://www.ema.europa.eu/documents/scientific-discussion/orgalutran-epar-scientific-discussion_en.pdf
EU-1-00-134,https://www.ema.europa.eu/documents/scientific-discussion/lantus-epar-scientific-discussion_en.pdf
EU-1-00-135,https://www.ema.europa.eu/documents/scientific-discussion/datscan-epar-scientific-discussion_en.pdf
EU-1-00-140,https://www.ema.europa.eu/documents/scientific-discussion/visudyne-epar-scientific-discussion_en.pdf
EU-1-00-142,https://www.ema.europa.eu/documents/scientific-discussion/novomix-epar-scientific-discussion_en.pdf
EU-1-00-143,https://www.ema.europa.eu/documents/scientific-discussion/kogenate-bayer-epar-scientific-discussion_en.pdf
EU-1-00-145,https://www.ema.europa.eu/documents/scientific-discussion/herceptin-epar-scientific-discussion_en.pdf
EU-1-00-146,https://www.ema.europa.eu/documents/scientific-discussion/keppra-epar-scientific-discussion_en.pdf
EU-1-00-149,https://www.ema.europa.eu/documents/scientific-discussion/panretin-epar-scientific-discussion_en.pdf
EU-1-00-152,https://www.ema.europa.eu/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf
EU-1-00-150,https://www.ema.europa.eu/documents/scientific-discussion/actos-epar-scientific-discussion_en.pdf
EU-1-00-155,https://www.ema.europa.eu/documents/assessment-report/luveris-epar-public-assessment-report_en.pdf
EU-1-00-156,https://www.ema.europa.eu/documents/scientific-discussion/trizivir-epar-scientific-discussion_en.pdf
EU-1-00-157,https://www.ema.europa.eu/documents/scientific-discussion/azomyr-epar-scientific-discussion_en.pdf
EU-1-00-160,https://www.ema.europa.eu/documents/scientific-discussion/aerius-epar-scientific-discussion_en.pdf
EU-1-00-161,https://www.ema.europa.eu/documents/scientific-discussion/neoclarityn-epar-scientific-discussion_en.pdf
EU-1-00-162,https://www.ema.europa.eu/documents/scientific-discussion/prandin-epar-scientific-discussion_en.pdf
EU-1-00-163,https://www.ema.europa.eu/documents/scientific-discussion/xeloda-epar-scientific-discussion_en.pdf
EU-1-00-166,https://www.ema.europa.eu/documents/scientific-discussion/neurobloc-epar-scientific-discussion_en.pdf
EU-1-00-165,https://www.ema.europa.eu/documents/scientific-discussion/ovitrelle-epar-scientific-discussion_en.pdf
EU-1-00-164,https://www.ema.europa.eu/documents/scientific-discussion/nutropinaq-epar-scientific-discussion_en.pdf
EU-1-00-169,https://www.ema.europa.eu/documents/scientific-discussion/metalyse-epar-scientific-discussion_en.pdf
EU-1-00-170,https://www.ema.europa.eu/documents/scientific-discussion/fasturtec-epar-scientific-discussion_en.pdf
EU-1-01-171,https://www.ema.europa.eu/documents/scientific-discussion/rapamune-epar-scientific-discussion_en.pdf
EU-1-01-172,https://www.ema.europa.eu/documents/scientific-discussion/kaletra-epar-scientific-discussion_en.pdf
EU-1-01-173,https://www.ema.europa.eu/documents/scientific-discussion/vaniqa-epar-scientific-discussion_en.pdf
EU-1-01-176,https://www.ema.europa.eu/documents/scientific-discussion/zometa-epar-scientific-discussion_en.pdf
EU-1-01-177,https://www.ema.europa.eu/documents/scientific-discussion/sonovue-epar-scientific-discussion_en.pdf
EU-1-01-178,https://www.ema.europa.eu/documents/assessment-report/targretin-epar-public-assessment-report_en.pdf
EU-1-01-183,https://www.ema.europa.eu/documents/scientific-discussion/hbvaxpro-epar-scientific-discussion_en.pdf
EU-1-01-185,https://www.ema.europa.eu/documents/scientific-discussion/aranesp-epar-scientific-discussion_en.pdf
EU-1-01-190,https://www.ema.europa.eu/documents/scientific-discussion/ceprotin-epar-scientific-discussion_en.pdf
EU-1-01-188,https://www.ema.europa.eu/documents/scientific-discussion/fabrazyme-epar-scientific-discussion_en.pdf
EU-1-01-189,https://www.ema.europa.eu/documents/scientific-discussion/replagal-epar-scientific-discussion_en.pdf
EU-1-01-194,https://www.ema.europa.eu/documents/scientific-discussion/inomax-epar-scientific-discussion_en.pdf
EU-1-01-195,https://www.ema.europa.eu/documents/scientific-discussion/liprolog-epar-scientific-discussion_en.pdf
EU-1-01-196,https://www.ema.europa.eu/documents/scientific-discussion/cancidas-epar-scientific-discussion_en.pdf
EU-1-01-197,https://www.ema.europa.eu/documents/scientific-discussion/foscan-epar-scientific-discussion_en.pdf
EU-1-01-198,https://www.ema.europa.eu/documents/scientific-discussion/glivec-epar-scientific-discussion_en.pdf
EU-1-01-199,https://www.ema.europa.eu/documents/scientific-discussion/travatan-epar-scientific-discussion_en.pdf
EU-1-01-200,https://www.ema.europa.eu/documents/scientific-discussion/viread-epar-scientific-discussion_en.pdf
EU-1-02-201,https://www.ema.europa.eu/documents/scientific-discussion/protopic-epar-scientific-discussion_en.pdf
EU-1-02-205,https://www.ema.europa.eu/documents/scientific-discussion/lumigan-epar-scientific-discussion_en.pdf
EU-1-02-203,https://www.ema.europa.eu/documents/scientific-discussion/kineret-epar-scientific-discussion_en.pdf
EU-1-02-209,https://www.ema.europa.eu/documents/scientific-discussion/dynastat-epar-scientific-discussion_en.pdf
EU-1-02-206,https://www.ema.europa.eu/documents/scientific-discussion/arixtra-epar-scientific-discussion_en.pdf
EU-1-02-212,https://www.ema.europa.eu/documents/scientific-discussion/vfend-epar-scientific-discussion_en.pdf
EU-1-02-214,https://www.ema.europa.eu/documents/scientific-discussion/kinzalkomb-epar-scientific-discussion_en.pdf
EU-1-02-215,https://www.ema.europa.eu/documents/scientific-discussion/pritorplus-epar-scientific-discussion_en.pdf
EU-1-02-213,https://www.ema.europa.eu/documents/scientific-discussion/micardisplus-epar-scientific-discussion_en.pdf
EU-1-02-216,https://www.ema.europa.eu/documents/scientific-discussion/invanz-epar-scientific-discussion_en.pdf
EU-1-02-217,https://www.ema.europa.eu/documents/scientific-discussion/opatanol-epar-scientific-discussion_en.pdf
EU-1-02-219,https://www.ema.europa.eu/documents/scientific-discussion/ebixa-epar-scientific-discussion_en.pdf
EU-1-02-218,https://www.ema.europa.eu/documents/scientific-discussion/axura-epar-scientific-discussion_en.pdf
EU-1-02-220,https://www.ema.europa.eu/documents/scientific-discussion/tracleer-epar-scientific-discussion_en.pdf
EU-1-02-221,https://www.ema.europa.eu/documents/scientific-discussion/pegasys-epar-scientific-discussion_en.pdf
EU-1-02-222,https://www.ema.europa.eu/documents/scientific-discussion/tamiflu-epar-scientific-discussion_en.pdf
EU-1-02-224,https://www.ema.europa.eu/documents/scientific-discussion/ambirix-epar-scientific-discussion_en.pdf
EU-1-02-223,https://www.ema.europa.eu/documents/scientific-discussion/evra-epar-scientific-discussion_en.pdf
EU-1-02-226,https://www.ema.europa.eu/documents/scientific-discussion/inductos-epar-scientific-discussion_en.pdf
EU-1-02-227,https://www.ema.europa.eu/documents/scientific-discussion/neulasta-epar-scientific-discussion_en.pdf
EU-1-02-229,https://www.ema.europa.eu/documents/scientific-discussion/actraphane-epar-scientific-discussion_en.pdf
EU-1-02-230,https://www.ema.europa.eu/documents/scientific-discussion/actrapid-epar-scientific-discussion_en.pdf
EU-1-02-234,https://www.ema.europa.eu/documents/scientific-discussion/protaphane-epar-scientific-discussion_en.pdf
EU-1-02-233,https://www.ema.europa.eu/documents/procedural-steps/insulatard-epar-procedural-steps-taken-authorisation_en.pdf
EU-1-02-231,https://www.ema.europa.eu/documents/scientific-discussion/mixtard-epar-scientific-discussion_en.pdf
EU-1-02-237,https://www.ema.europa.eu/documents/scientific-discussion/cialis-epar-scientific-discussion_en.pdf
EU-1-02-240,https://www.ema.europa.eu/documents/scientific-discussion/somavert-epar-scientific-discussion_en.pdf
EU-1-02-238,https://www.ema.europa.eu/documents/scientific-discussion/zavesca-epar-scientific-discussion_en.pdf
EU-1-02-246,https://www.ema.europa.eu/documents/scientific-discussion/carbaglu-epar-scientific-discussion_en.pdf
EU-1-03-248,https://www.ema.europa.eu/documents/scientific-discussion/levitra-epar-scientific-discussion_en.pdf
EU-1-03-251,https://www.ema.europa.eu/documents/scientific-discussion/hepsera-epar-scientific-discussion_en.pdf
EU-1-03-249,https://www.ema.europa.eu/documents/scientific-discussion/vivanza-epar-scientific-discussion_en.pdf
EU-1-03-247,https://www.ema.europa.eu/documents/scientific-discussion/forsteo-epar-scientific-discussion_en.pdf
EU-1-03-252,https://www.ema.europa.eu/documents/scientific-discussion/fuzeon-epar-scientific-discussion_en.pdf
EU-1-03-253,https://www.ema.europa.eu/documents/scientific-discussion/aldurazyme-epar-scientific-discussion_en.pdf
EU-1-03-254,https://www.ema.europa.eu/documents/scientific-discussion/busilvex-epar-scientific-discussion_en.pdf
EU-1-03-255,https://www.ema.europa.eu/documents/scientific-discussion/ventavis-epar-scientific-discussion_en.pdf
EU-1-03-256,https://www.ema.europa.eu/documents/scientific-discussion/humira-epar-scientific-discussion_en.pdf
EU-1-03-260,https://www.ema.europa.eu/documents/scientific-discussion/stalevo-epar-scientific-discussion_en.pdf
EU-1-03-262,https://www.ema.europa.eu/documents/scientific-discussion/emend-epar-scientific-discussion_en.pdf
EU-1-03-263,https://www.ema.europa.eu/documents/scientific-discussion/dukoral-epar-scientific-discussion_en.pdf
EU-1-03-261,https://www.ema.europa.eu/documents/scientific-discussion/emtriva-epar-scientific-discussion_en.pdf
EU-1-03-264,https://www.ema.europa.eu/documents/scientific-discussion/zevalin-epar-scientific-discussion_en.pdf
EU-1-03-265,https://www.ema.europa.eu/documents/scientific-discussion/bonviva-epar-scientific-discussion_en.pdf
EU-1-03-269,https://www.ema.europa.eu/documents/assessment-report/faslodex-epar-public-assessment-report_en.pdf
EU-1-03-270,https://www.ema.europa.eu/documents/scientific-discussion/kentera-epar-scientific-discussion_en.pdf
EU-1-03-267,https://www.ema.europa.eu/documents/scientific-discussion/reyataz-epar-scientific-discussion_en.pdf
EU-1-03-268,https://www.ema.europa.eu/documents/scientific-discussion/cholestagel-epar-scientific-discussion_en.pdf
EU-1-10-639,https://www.ema.europa.eu/documents/assessment-report/telmisartan-actavis-epar-public-assessment-report_en.pdf
EU-1-10-642,https://www.ema.europa.eu/documents/assessment-report/ibandronic-acid-teva-epar-public-assessment-report_en.pdf
EU-1-10-641,https://www.ema.europa.eu/documents/assessment-report/ruconest-epar-public-assessment-report_en.pdf
EU-1-10-640,https://www.ema.europa.eu/documents/assessment-report/sycrest-epar-public-assessment-report_en.pdf
EU-1-10-643,https://www.ema.europa.eu/documents/assessment-report/rapiscan-epar-public-assessment-report_en.pdf
EU-1-10-644,https://www.ema.europa.eu/documents/assessment-report/pecfent-epar-public-assessment-report_en.pdf
EU-1-10-646,https://www.ema.europa.eu/documents/assessment-report/vpriv-epar-public-assessment-report_en.pdf
EU-1-10-645,https://www.ema.europa.eu/documents/assessment-report/brinavess-epar-public-assessment-report_en.pdf
EU-1-10-647,https://www.ema.europa.eu/documents/assessment-report/myclausen-epar-public-assessment-report_en.pdf
EU-1-10-648,https://www.ema.europa.eu/documents/assessment-report/twynsta-epar-public-assessment-report_en.pdf
EU-1-10-654,https://www.ema.europa.eu/documents/assessment-report/leflunomide-ratiopharm-epar-public-assessment-report_en.pdf
EU-1-10-652,https://www.ema.europa.eu/documents/assessment-report/tobi-podhaler-epar-public-assessment-report_en.pdf
EU-1-10-655,https://www.ema.europa.eu/documents/assessment-report/brilique-epar-public-assessment-report_en.pdf
EU-1-10-658,https://www.ema.europa.eu/documents/assessment-report/aflunov-epar-public-assessment-report_en.pdf
EU-1-10-659,https://www.ema.europa.eu/documents/assessment-report/iasibon-epar-public-assessment-report_en.pdf
EU-1-10-660,https://www.ema.europa.eu/documents/assessment-report/potactasol-epar-public-assessment-report_en.pdf
EU-1-10-663,https://www.ema.europa.eu/documents/assessment-report/lamivudine/zidovudine-teva-epar-public-assessment-report_en.pdf
EU-1-10-665,https://www.ema.europa.eu/documents/assessment-report/entacapone-teva-epar-public-assessment-report_en.pdf
EU-1-11-667,https://www.ema.europa.eu/documents/assessment-report/esbriet-epar-public-assessment-report_en.pdf
EU-1-11-672,https://www.ema.europa.eu/documents/assessment-report/xeplion-epar-public-assessment-report_en.pdf
EU-1-11-669,https://www.ema.europa.eu/documents/assessment-report/teysuno-epar-public-assessment-report_en.pdf
EU-1-13-870,https://www.ema.europa.eu/documents/assessment-report/orphacol-epar-public-assessment-report_en.pdf
EU-1-11-673,https://www.ema.europa.eu/documents/assessment-report/ifirmacombi-epar-public-assessment-report_en.pdf
EU-1-10-637,https://www.ema.europa.eu/documents/assessment-report/leflunomide-medac-epar-public-assessment-report_en.pdf
EU-1-11-676,https://www.ema.europa.eu/documents/assessment-report/jevtana-epar-public-assessment-report_en.pdf
EU-1-11-677,https://www.ema.europa.eu/documents/assessment-report/gilenya-epar-public-assessment-report_en.pdf
EU-1-11-678,https://www.ema.europa.eu/documents/assessment-report/halaven-epar-public-assessment-report_en.pdf
EU-1-11-679,https://www.ema.europa.eu/documents/assessment-report/pravafenix-epar-public-assessment-report_en.pdf
EU-1-11-682,https://www.ema.europa.eu/documents/assessment-report/methylthioninium-chloride-proveblue-epar-public-assessment-report_en.pdf
EU-1-11-685,https://www.ema.europa.eu/documents/assessment-report/ibandronic-acid-sandoz-epar-public-assessment-report_en.pdf
EU-1-11-687,https://www.ema.europa.eu/documents/assessment-report/hizentra-epar-public-assessment-report_en.pdf
EU-1-11-690,https://www.ema.europa.eu/documents/assessment-report/zoely-epar-public-assessment-report_en.pdf
EU-1-11-692,https://www.ema.europa.eu/documents/assessment-report/yellox-epar-public-assessment-report_en.pdf
EU-1-11-691,https://www.ema.europa.eu/documents/assessment-report/eliquis-epar-public-assessment-report_en.pdf
EU-1-11-693,https://www.ema.europa.eu/documents/assessment-report/rivastigmine-actavis-epar-public-assessment-report_en.pdf
EU-1-11-688,https://www.ema.europa.eu/documents/assessment-report/cinryze-epar-public-assessment-report_en.pdf
EU-1-11-694,https://www.ema.europa.eu/documents/assessment-report/nulojix-epar-public-assessment-report_en.pdf
EU-1-11-697,https://www.ema.europa.eu/documents/assessment-report/temozolomide-sun-epar-public-assessment-report_en.pdf
EU-1-11-698,https://www.ema.europa.eu/documents/assessment-report/yervoy-epar-public-assessment-report_en.pdf
EU-1-11-699,https://www.ema.europa.eu/documents/assessment-report/fampyra-epar-public-assessment-report_en.pdf
EU-1-11-700,https://www.ema.europa.eu/documents/assessment-report/benlysta-epar-public-assessment-report_en.pdf
EU-1-11-701,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-teva-epar-public-assessment-report_en.pdf
EU-1-11-702,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-ratiopharm-epar-public-assessment-report_en.pdf
EU-1-11-703,https://www.ema.europa.eu/documents/assessment-report/xgeva-epar-public-assessment-report_en.pdf
EU-1-11-707,https://www.ema.europa.eu/documents/assessment-report/trajenta-epar-public-assessment-report_en.pdf
EU-1-11-706,https://www.ema.europa.eu/documents/assessment-report/levodopa/carbidopa/entacapone-orion-epar-public-assessment-report_en.pdf
EU-1-11-708,https://www.ema.europa.eu/documents/assessment-report/entacapone-orion-epar-public-assessment-report_en.pdf
EU-1-11-709,https://www.ema.europa.eu/documents/assessment-report/buccolam-epar-public-assessment-report_en.pdf
EU-1-11-710,https://www.ema.europa.eu/documents/assessment-report/votubia-epar-public-assessment-report_en.pdf
EU-1-11-713,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-actavis-epar-public-assessment-report_en.pdf
EU-1-11-712,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-accord-epar-public-assessment-report_en.pdf
EU-1-11-711,https://www.ema.europa.eu/documents/assessment-report/matever-epar-public-assessment-report_en.pdf
EU-1-11-714,https://www.ema.europa.eu/documents/assessment-report/zytiga-epar-public-assessment-report_en.pdf
EU-1-11-716,https://www.ema.europa.eu/documents/assessment-report/eurartesim-epar-public-assessment-report_en.pdf
EU-1-11-719,https://www.ema.europa.eu/documents/assessment-report/telmisartan-teva-pharma-epar-public-assessment-report_en.pdf
EU-1-11-717,https://www.ema.europa.eu/documents/assessment-report/vyndaqel-epar-public-assessment-report_en.pdf
EU-1-11-718,https://www.ema.europa.eu/documents/assessment-report/dexdor-epar-public-assessment-report_en.pdf
EU-1-11-722,https://www.ema.europa.eu/documents/assessment-report/pioglitazone-accord-epar-public-assessment-report_en.pdf
EU-1-11-727,https://www.ema.europa.eu/documents/assessment-report/mercaptopurine-nova-laboratories-epar-public-assessment-report_en.pdf
EU-1-11-715,https://www.ema.europa.eu/documents/assessment-report/plenadren-epar-public-assessment-report_en.pdf
EU-1-11-732,https://www.ema.europa.eu/documents/assessment-report/desloratadine-teva-epar-public-assessment-report_en.pdf
EU-1-11-731,https://www.ema.europa.eu/documents/assessment-report/komboglyze-epar-public-assessment-report_en.pdf
EU-1-11-734,https://www.ema.europa.eu/documents/assessment-report/edarbi-epar-public-assessment-report_en.pdf
EU-1-11-736,https://www.ema.europa.eu/documents/assessment-report/edurant-epar-public-assessment-report_en.pdf
EU-1-11-737,https://www.ema.europa.eu/documents/assessment-report/eviplera-epar-public-assessment-report_en.pdf
EU-1-11-733,https://www.ema.europa.eu/documents/assessment-report/dificlir-epar-public-assessment-report_en.pdf
EU-1-11-738,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-actavis-group-epar-public-assessment-report_en.pdf
EU-1-11-739,https://www.ema.europa.eu/documents/assessment-report/dasselta-epar-public-assessment-report_en.pdf
EU-1-11-740,https://www.ema.europa.eu/documents/assessment-report/ameluz-epar-public-assessment-report_en.pdf
EU-1-11-741,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-sun-epar-public-assessment-report_en.pdf
EU-1-11-742,https://www.ema.europa.eu/documents/assessment-report/efavirenz-teva-epar-public-assessment-report_en.pdf
EU-1-11-743,https://www.ema.europa.eu/documents/assessment-report/repaglinide-accord-epar-public-assessment-report_en.pdf
EU-1-11-745,https://www.ema.europa.eu/documents/assessment-report/desloratadine-actavis-epar-public-assessment-report_en.pdf
EU-1-11-746,https://www.ema.europa.eu/documents/assessment-report/desloratadine-ratiopharm-epar-public-assessment-report_en.pdf
EU-1-11-749,https://www.ema.europa.eu/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
EU-1-11-747,https://www.ema.europa.eu/documents/assessment-report/colobreathe-epar-public-assessment-report_en.pdf
EU-1-12-750,https://www.ema.europa.eu/documents/assessment-report/esmya-epar-public-assessment-report_en.pdf
EU-1-12-751,https://www.ema.europa.eu/documents/assessment-report/zelboraf-epar-public-assessment-report_en.pdf
EU-1-12-753,https://www.ema.europa.eu/documents/assessment-report/signifor-epar-public-assessment-report_en.pdf
EU-1-12-755,https://www.ema.europa.eu/documents/assessment-report/pioglitazone-actavis-epar-public-assessment-report_en.pdf
EU-1-12-757,https://www.ema.europa.eu/documents/assessment-report/pioglitazone-teva-epar-public-assessment-report_en.pdf
EU-1-12-759,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-actavis-epar-public-assessment-report_en.pdf
EU-1-12-762,https://www.ema.europa.eu/documents/assessment-report/capecitabine-accord-epar-public-assessment-report_en.pdf
EU-1-12-761,https://www.ema.europa.eu/documents/assessment-report/capecitabine-teva-epar-public-assessment-report_en.pdf
EU-1-12-763,https://www.ema.europa.eu/documents/assessment-report/capecitabine-krka-epar-public-assessment-report_en.pdf
EU-1-12-760,https://www.ema.europa.eu/documents/assessment-report/bronchitol-epar-public-assessment-report_en.pdf
EU-1-12-764,https://www.ema.europa.eu/documents/assessment-report/pixuvri-epar-public-assessment-report_en.pdf
EU-1-12-766,https://www.ema.europa.eu/documents/assessment-report/sancuso-epar-public-assessment-report_en.pdf
EU-1-12-767,https://www.ema.europa.eu/documents/assessment-report/nimenrix-epar-public-assessment-report_en.pdf
EU-1-12-768,https://www.ema.europa.eu/documents/assessment-report/riluzole-zentiva-epar-public-assessment-report_en.pdf
EU-1-12-771,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-teva-epar-public-assessment-report_en.pdf
EU-1-12-769,https://www.ema.europa.eu/documents/assessment-report/docetaxel-accord-epar-public-assessment-report_en.pdf
EU-1-12-770,https://www.ema.europa.eu/documents/assessment-report/docetaxel-kabi-epar-public-assessment-report_en.pdf
EU-1-12-773,https://www.ema.europa.eu/documents/assessment-report/jakavi-epar-public-assessment-report_en.pdf
EU-1-12-775,https://www.ema.europa.eu/documents/assessment-report/novothirteen-epar-public-assessment-report_en.pdf
EU-1-12-776,https://www.ema.europa.eu/documents/assessment-report/fycompa-epar-public-assessment-report_en.pdf
EU-1-12-777,https://www.ema.europa.eu/documents/assessment-report/inlyta-epar-public-assessment-report_en.pdf
EU-1-12-778,https://www.ema.europa.eu/documents/assessment-report/eklira-genuair-epar-public-assessment-report_en.pdf
EU-1-12-779,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-medac-epar-public-assessment-report_en.pdf
EU-1-12-780,https://www.ema.europa.eu/documents/assessment-report/jentadueto-epar-public-assessment-report_en.pdf
EU-1-12-781,https://www.ema.europa.eu/documents/assessment-report/bretaris-genuair-epar-public-assessment-report_en.pdf
EU-1-12-782,https://www.ema.europa.eu/documents/assessment-report/kalydeco-epar-public-assessment-report_en.pdf
EU-1-12-783,https://www.ema.europa.eu/documents/assessment-report/zyclara-epar-public-assessment-report_en.pdf
EU-1-12-784,https://www.ema.europa.eu/documents/assessment-report/cuprymina-epar-public-assessment-report_en.pdf
EU-1-12-785,https://www.ema.europa.eu/documents/assessment-report/zinforo-epar-public-assessment-report_en.pdf
EU-1-12-786,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-mylan-epar-public-assessment-report_en.pdf
EU-1-12-787,https://www.ema.europa.eu/documents/assessment-report/revestive-epar-public-assessment-report_en.pdf
EU-1-12-788,https://www.ema.europa.eu/documents/assessment-report/seebri-breezhaler-epar-public-assessment-report_en.pdf
EU-1-12-789,https://www.ema.europa.eu/documents/assessment-report/enurev-breezhaler-epar-public-assessment-report_en.pdf
EU-1-12-790,https://www.ema.europa.eu/documents/assessment-report/tovanor-breezhaler-epar-public-assessment-report_en.pdf
EU-1-12-792,https://www.ema.europa.eu/documents/assessment-report/dacogen-epar-public-assessment-report_en.pdf
EU-1-12-793,https://www.ema.europa.eu/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf
EU-1-12-794,https://www.ema.europa.eu/documents/assessment-report/adcetris-epar-public-assessment-report_en.pdf
EU-1-12-795,https://www.ema.europa.eu/documents/assessment-report/forxiga-epar-public-assessment-report_en.pdf
EU-1-12-797,https://www.ema.europa.eu/documents/assessment-report/eylea-epar-public-assessment-report_en.pdf
EU-1-12-800,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-hospira-epar-public-assessment-report_en.pdf
EU-1-12-801,https://www.ema.europa.eu/documents/assessment-report/constella-epar-public-assessment-report_en.pdf
EU-1-12-798,https://www.ema.europa.eu/documents/assessment-report/ibandronic-acid-accord-epar-public-assessment-report_en.pdf
EU-1-12-799,https://www.ema.europa.eu/documents/assessment-report/memantine-merz-epar-public-assessment-report_en.pdf
EU-1-12-802,https://www.ema.europa.eu/documents/assessment-report/capecitabine-medac-epar-public-assessment-report_en.pdf
EU-1-12-803,https://www.ema.europa.eu/documents/assessment-report/nexobrid-epar-public-assessment-report_en.pdf
EU-1-12-805,https://www.ema.europa.eu/documents/assessment-report/amyvid-epar-public-assessment-report_en.pdf
EU-1-12-806,https://www.ema.europa.eu/documents/assessment-report/ryzodeg-epar-public-assessment-report_en.pdf
EU-1-12-808,https://www.ema.europa.eu/documents/assessment-report/imatinib-teva-epar-public-assessment-report_en.pdf
EU-1-12-807,https://www.ema.europa.eu/documents/assessment-report/tresiba-epar-public-assessment-report_en.pdf
EU-1-08-448,https://www.ema.europa.eu/documents/assessment-report/mycamine-epar-public-assessment-report_en.pdf
EU-1-08-451,https://www.ema.europa.eu/documents/assessment-report/volibris-epar-public-assessment-report_en.pdf
EU-1-08-444,https://www.ema.europa.eu/documents/assessment-report/ratiograstim-epar-public-assessment-report_en.pdf
EU-1-08-445,https://www.ema.europa.eu/documents/assessment-report/tevagrastim-epar-public-assessment-report_en.pdf
EU-1-08-454,https://www.ema.europa.eu/documents/assessment-report/extavia-epar-public-assessment-report_en.pdf
EU-1-08-462,https://www.ema.europa.eu/documents/assessment-report/ranexa-epar-public-assessment-report_en.pdf
EU-1-08-463,https://www.ema.europa.eu/documents/assessment-report/relistor-epar-public-assessment-report_en.pdf
EU-1-08-461,https://www.ema.europa.eu/documents/assessment-report/firazyr-epar-public-assessment-report_en.pdf
EU-1-08-457,https://www.ema.europa.eu/documents/assessment-report/efficib-epar-public-assessment-report_en.pdf
EU-1-08-455,https://www.ema.europa.eu/documents/assessment-report/janumet-epar-public-assessment-report_en.pdf
EU-1-08-456,https://www.ema.europa.eu/documents/assessment-report/velmetia-epar-public-assessment-report_en.pdf
EU-1-08-465,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-winthrop-epar-public-assessment-report_en.pdf
EU-1-08-466,https://www.ema.europa.eu/documents/assessment-report/bridion-epar-public-assessment-report_en.pdf
EU-1-08-468,https://www.ema.europa.eu/documents/assessment-report/intelence-epar-public-assessment-report_en.pdf
EU-1-08-469,https://www.ema.europa.eu/documents/assessment-report/oprymea-epar-public-assessment-report_en.pdf
EU-1-08-470,https://www.ema.europa.eu/documents/assessment-report/vimpat-epar-public-assessment-report_en.pdf
EU-1-08-475,https://www.ema.europa.eu/documents/assessment-report/olanzapine-mylan-epar-public-assessment-report_en.pdf
EU-1-08-472,https://www.ema.europa.eu/documents/assessment-report/xarelto-epar-public-assessment-report_en.pdf
EU-1-08-473,https://www.ema.europa.eu/documents/assessment-report/evicel-epar-public-assessment-report_en.pdf
EU-1-08-476,https://www.ema.europa.eu/documents/assessment-report/tadalafil-lilly-epar-public-assessment-report_en-0.pdf
EU-1-08-477,https://www.ema.europa.eu/documents/assessment-report/ceplene-epar-public-assessment-report_en.pdf
EU-1-08-479,https://www.ema.europa.eu/documents/assessment-report/zypadhera-epar-public-assessment-report_en.pdf
EU-1-08-480,https://www.ema.europa.eu/documents/assessment-report/ifirmasta-epar-public-assessment-report_en.pdf
EU-1-08-481,https://www.ema.europa.eu/documents/assessment-report/kuvan-epar-public-assessment-report_en.pdf
EU-1-08-483,https://www.ema.europa.eu/documents/assessment-report/zomarist-epar-public-assessment-report_en.pdf
EU-1-08-482,https://www.ema.europa.eu/documents/assessment-report/azarga-epar-public-assessment-report_en.pdf
EU-1-08-485,https://www.ema.europa.eu/documents/assessment-report/jalra-epar-public-assessment-report_en.pdf
EU-1-08-486,https://www.ema.europa.eu/documents/assessment-report/xiliarx-epar-public-assessment-report_en.pdf
EU-1-08-484,https://www.ema.europa.eu/documents/assessment-report/icandra-epar-public-assessment-report_en.pdf
EU-1-08-490,https://www.ema.europa.eu/documents/assessment-report/pramipexole-teva-epar-public-assessment-report_en.pdf
EU-1-08-488,https://www.ema.europa.eu/documents/assessment-report/vidaza-epar-public-assessment-report_en.pdf
EU-1-08-492,https://www.ema.europa.eu/documents/assessment-report/roactemra-epar-public-assessment-report_en.pdf
EU-1-08-494,https://www.ema.europa.eu/documents/assessment-report/stelara-epar-public-assessment-report_en.pdf
EU-1-08-495,https://www.ema.europa.eu/documents/assessment-report/zarzio-epar-public-assessment-report_en.pdf
EU-1-08-497,https://www.ema.europa.eu/documents/assessment-report/nplate-epar-public-assessment-report_en.pdf
EU-1-08-496,https://www.ema.europa.eu/documents/assessment-report/filgrastim-hexal-epar-public-assessment-report_en.pdf
EU-1-08-498,https://www.ema.europa.eu/documents/assessment-report/thymanax-epar-public-assessment-report_en.pdf
EU-1-08-499,https://www.ema.europa.eu/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf
EU-1-08-501,https://www.ema.europa.eu/documents/assessment-report/ixiaro-epar-public-assessment-report_en.pdf
EU-1-08-502,https://www.ema.europa.eu/documents/assessment-report/mepact-epar-public-assessment-report_en.pdf
EU-1-08-503,https://www.ema.europa.eu/documents/assessment-report/efient-epar-public-assessment-report_en.pdf
EU-1-08-504,https://www.ema.europa.eu/documents/assessment-report/firmagon-epar-public-assessment-report_en.pdf
EU-1-09-508,https://www.ema.europa.eu/documents/assessment-report/synflorix-epar-public-assessment-report_en.pdf
EU-1-09-511,https://www.ema.europa.eu/documents/assessment-report/conbriza-epar-public-assessment-report_en.pdf
EU-1-09-514,https://www.ema.europa.eu/documents/assessment-report/zebinix-epar-public-assessment-report_en.pdf
EU-1-09-515,https://www.ema.europa.eu/documents/assessment-report/controloc-control-epar-public-assessment-report_en.pdf
EU-1-09-516,https://www.ema.europa.eu/documents/assessment-report/somac-control-epar-public-assessment-report_en.pdf
EU-1-09-517,https://www.ema.europa.eu/documents/assessment-report/pantozol-control-epar-public-assessment-report_en.pdf
EU-1-09-523,https://www.ema.europa.eu/documents/assessment-report/modigraf-epar-public-assessment-report_en.pdf
EU-1-09-524,https://www.ema.europa.eu/documents/assessment-report/qutenza-epar-public-assessment-report_en.pdf
EU-1-09-525,https://www.ema.europa.eu/documents/assessment-report/nimvastid-epar-public-assessment-report_en.pdf
EU-1-09-521,https://www.ema.europa.eu/documents/assessment-report/renvela-epar-public-assessment-report_en.pdf
EU-1-09-522,https://www.ema.europa.eu/documents/assessment-report/ellaone-epar-public-assessment-report_en.pdf
EU-1-09-526,https://www.ema.europa.eu/documents/assessment-report/iressa-epar-public-assessment-report_en.pdf
EU-1-09-528,https://www.ema.europa.eu/documents/assessment-report/nymusa-epar-public-assessment-report_en.pdf
EU-1-09-529,https://www.ema.europa.eu/documents/assessment-report/victoza-epar-public-assessment-report_en.pdf
EU-1-09-530,https://www.ema.europa.eu/documents/assessment-report/repaglinide-teva-epar-public-assessment-report_en.pdf
EU-1-09-531,https://www.ema.europa.eu/documents/assessment-report/instanyl-epar-public-assessment-report_en.pdf
EU-1-09-533,https://www.ema.europa.eu/documents/assessment-report/vedrop-epar-public-assessment-report_en.pdf
EU-1-09-535,https://www.ema.europa.eu/documents/assessment-report/grepid-epar-public-assessment-report_en.pdf
EU-1-09-538,https://www.ema.europa.eu/documents/assessment-report/afinitor-epar-public-assessment-report_en.pdf
EU-1-09-537,https://www.ema.europa.eu/documents/assessment-report/mozobil-epar-public-assessment-report_en.pdf
EU-1-09-539,https://www.ema.europa.eu/documents/assessment-report/samsca-epar-public-assessment-report_en.pdf
EU-1-09-540,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-teva-hydrogen-sulphate-epar-public-assessment-report_en.pdf
EU-1-09-546,https://www.ema.europa.eu/documents/assessment-report/simponi-epar-public-assessment-report_en.pdf
EU-1-09-545,https://www.ema.europa.eu/documents/assessment-report/onglyza-epar-public-assessment-report_en.pdf
EU-1-09-544,https://www.ema.europa.eu/documents/assessment-report/cimzia-epar-public-assessment-report_en.pdf
EU-1-09-553,https://www.ema.europa.eu/documents/assessment-report/zyllt-epar-public-assessment-report_en.pdf
EU-1-09-558,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-bgr-previously-zylagren-epar-public-assessment-report_en.pdf
EU-1-09-562,https://www.ema.europa.eu/documents/assessment-report/zopya-epar-public-assessment-report_en.pdf
EU-1-09-556,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-krka-epar-public-assessment-report_en.pdf
EU-1-09-543,https://www.ema.europa.eu/documents/assessment-report/cayston-epar-public-assessment-report_en.pdf
EU-1-09-555,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-tad-epar-public-assessment-report_en.pdf
EU-1-09-550,https://www.ema.europa.eu/documents/assessment-report/javlor-epar-public-assessment-report_en.pdf
EU-1-09-551,https://www.ema.europa.eu/documents/assessment-report/vizarsin-epar-public-assessment-report_en.pdf
EU-1-09-565,https://www.ema.europa.eu/documents/assessment-report/biopoin-epar-public-assessment-report_en.pdf
EU-1-09-566,https://www.ema.europa.eu/documents/assessment-report/lamivudine-teva-epar-public-assessment-report_en.pdf
EU-1-09-564,https://www.ema.europa.eu/documents/assessment-report/ilaris-epar-public-assessment-report_en.pdf
EU-1-09-573,https://www.ema.europa.eu/documents/assessment-report/eporatio-epar-public-assessment-report_en.pdf
EU-1-09-576,https://www.ema.europa.eu/documents/assessment-report/irbesartan-teva-epar-public-assessment-report_en.pdf
EU-1-09-577,https://www.ema.europa.eu/documents/assessment-report/foclivia-epar-public-assessment-report_en.pdf
EU-1-09-575,https://www.ema.europa.eu/documents/assessment-report/copalia-hct-epar-public-assessment-report_en.pdf
EU-1-09-574,https://www.ema.europa.eu/documents/assessment-report/dafiro-hct-epar-public-assessment-report_en.pdf
EU-1-09-579,https://www.ema.europa.eu/documents/assessment-report/repaglinide-krka-epar-public-assessment-report_en.pdf
EU-1-09-569,https://www.ema.europa.eu/documents/assessment-report/exforge-hct-epar-public-assessment-report_en.pdf
EU-1-09-572,https://www.ema.europa.eu/documents/assessment-report/alendronate-sodium/colecalciferol-msd-epar-public-assessment-report_en.pdf
EU-1-09-571,https://www.ema.europa.eu/documents/assessment-report/pandemic-influenza-vaccine-h5n1-baxter-epar-public-assessment-report_en.pdf
EU-1-09-580,https://www.ema.europa.eu/documents/assessment-report/enyglid-epar-public-assessment-report_en.pdf
EU-1-09-581,https://www.ema.europa.eu/documents/assessment-report/resolor-epar-public-assessment-report_en.pdf
EU-1-09-583,https://www.ema.europa.eu/documents/assessment-report/irbesartan/hydrochlorothiazide-teva-epar-public-assessment-report_en.pdf
EU-1-09-589,https://www.ema.europa.eu/documents/assessment-report/rivastigmine-hexal-epar-public-assessment-report_en.pdf
EU-1-09-584,https://www.ema.europa.eu/documents/assessment-report/sildenafil-teva-epar-public-assessment-report_en.pdf
EU-1-09-586,https://www.ema.europa.eu/documents/assessment-report/oslif-breezhaler-epar-public-assessment-report_en.pdf
EU-1-09-590,https://www.ema.europa.eu/documents/assessment-report/prevenar-13-epar-public-assessment-report_en.pdf
EU-1-09-587,https://www.ema.europa.eu/documents/assessment-report/olanzapine-glenmark-epar-public-assessment-report_en.pdf
EU-1-09-588,https://www.ema.europa.eu/documents/assessment-report/olanzapine-glenmark-europe-epar-public-assessment-report_en.pdf
EU-1-09-591,https://www.ema.europa.eu/documents/assessment-report/multaq-epar-public-assessment-report_en.pdf
EU-1-09-592,https://www.ema.europa.eu/documents/assessment-report/olazax-disperzi-epar-public-assessment-report_en.pdf
EU-1-09-597,https://www.ema.europa.eu/documents/assessment-report/olazax-epar-public-assessment-report_en.pdf
EU-1-09-598,https://www.ema.europa.eu/documents/assessment-report/nevirapine-teva-epar-public-assessment-report_en.pdf
EU-1-09-593,https://www.ema.europa.eu/documents/assessment-report/onbrez-breezhaler-epar-public-assessment-report_en.pdf
EU-1-09-599,https://www.ema.europa.eu/documents/assessment-report/rivastigmine-sandoz-epar-public-assessment-report_en.pdf
EU-1-09-594,https://www.ema.europa.eu/documents/assessment-report/hirobriz-breezhaler-epar-public-assessment-report_en.pdf
EU-1-09-600,https://www.ema.europa.eu/documents/assessment-report/zutectra-epar-public-assessment-report_en.pdf
EU-1-09-596,https://www.ema.europa.eu/documents/assessment-report/lamivudine-teva-pharma-bv-epar-public-assessment-report_en.pdf
EU-1-09-595,https://www.ema.europa.eu/documents/assessment-report/sildenafil-actavis-epar-public-assessment-report_en.pdf
EU-1-09-601,https://www.ema.europa.eu/documents/assessment-report/firdapse-epar-public-assessment-report_en.pdf
EU-1-09-603,https://www.ema.europa.eu/documents/assessment-report/sildenafil-ratiopharm-epar-public-assessment-report_en.pdf
EU-1-09-602,https://www.ema.europa.eu/documents/assessment-report/scintimun-epar-public-assessment-report_en.pdf
EU-1-09-604,https://www.ema.europa.eu/documents/assessment-report/leflunomide-winthrop-epar-public-assessment-report_en.pdf
EU-1-09-609,https://www.ema.europa.eu/documents/assessment-report/elonva-epar-public-assessment-report_en.pdf
EU-1-09-606,https://www.ema.europa.eu/documents/assessment-report/temozolomide-teva-epar-public-assessment-report_en.pdf
EU-1-09-607,https://www.ema.europa.eu/documents/assessment-report/silodyx-epar-public-assessment-report_en.pdf
EU-1-09-608,https://www.ema.europa.eu/documents/assessment-report/urorec-epar-public-assessment-report_en.pdf
EU-1-10-612,https://www.ema.europa.eu/documents/assessment-report/revolade-epar-public-assessment-report_en.pdf
EU-1-10-614,https://www.ema.europa.eu/documents/assessment-report/menveo-epar-public-assessment-report_en.pdf
EU-1-10-618,https://www.ema.europa.eu/documents/assessment-report/prolia-epar-public-assessment-report_en.pdf
EU-1-10-619,https://www.ema.europa.eu/documents/assessment-report/duoplavin-epar-public-assessment-report_en.pdf
EU-1-10-622,https://www.ema.europa.eu/documents/assessment-report/tepadina-epar-public-assessment-report_en.pdf
EU-1-10-620,https://www.ema.europa.eu/documents/assessment-report/ristfor-epar-public-assessment-report_en.pdf
EU-1-10-621,https://www.ema.europa.eu/documents/assessment-report/ristaben-epar-public-assessment-report_en.pdf
EU-1-10-627,https://www.ema.europa.eu/documents/assessment-report/raloxifene-teva-epar-public-assessment-report_en.pdf
EU-1-10-628,https://www.ema.europa.eu/documents/assessment-report/votrient-epar-public-assessment-report_en.pdf
EU-1-10-631,https://www.ema.europa.eu/documents/assessment-report/nivestim-epar-public-assessment-report_en.pdf
EU-1-10-632,https://www.ema.europa.eu/documents/assessment-report/tolura-epar-public-assessment-report_en.pdf
EU-1-10-635,https://www.ema.europa.eu/documents/assessment-report/olanzapine-apotex-epar-public-assessment-report_en.pdf
EU-1-10-633,https://www.ema.europa.eu/documents/assessment-report/topotecan-hospira-epar-public-assessment-report_en.pdf
EU-1-10-636,https://www.ema.europa.eu/documents/assessment-report/daxas-epar-public-assessment-report_en.pdf
EU-1-10-638,https://www.ema.europa.eu/documents/assessment-report/ozurdex-epar-public-assessment-report_en.pdf
EU-1-15-1076,https://www.ema.europa.eu/documents/assessment-report/kovaltry-epar-public-assessment-report_en.pdf
EU-1-15-1078,https://www.ema.europa.eu/documents/assessment-report/natpar-epar-public-assessment-report_en.pdf
EU-1-15-1056,https://www.ema.europa.eu/documents/assessment-report/praxbind-epar-public-assessment-report_en.pdf
EU-1-16-1086,https://www.ema.europa.eu/documents/assessment-report/tagrisso-epar-public-assessment-report_en.pdf
EU-1-18-1298,https://www.ema.europa.eu/documents/assessment-report/veyvondi-epar-public-assessment-report_en.pdf
EU-1-15-1025,https://www.ema.europa.eu/documents/assessment-report/evotaz-epar-public-assessment-report_en.pdf
EU-1-18-1273,https://www.ema.europa.eu/documents/assessment-report/prasugrel-mylan-epar-public-assessment-report_en.pdf
EU-1-12-809,https://www.ema.europa.eu/documents/assessment-report/betmiga-epar-public-assessment-report_en.pdf
EU-1-14-945,https://www.ema.europa.eu/documents/assessment-report/imbruvica-epar-public-assessment-report_en.pdf
EU-1-14-946,https://www.ema.europa.eu/documents/assessment-report/accofil-epar-public-assessment-report_en.pdf
EU-1-12-812,https://www.ema.europa.eu/documents/assessment-report/bexsero-epar-public-assessment-report_en.pdf
EU-1-13-819,https://www.ema.europa.eu/documents/assessment-report/jetrea-epar-public-assessment-report_en.pdf
EU-1-13-884,https://www.ema.europa.eu/documents/assessment-report/invokana-epar-public-assessment-report_en.pdf
EU-1-13-894,https://www.ema.europa.eu/documents/assessment-report/sovaldi-epar-public-assessment-report_en.pdf
EU-1-14-918,https://www.ema.europa.eu/documents/assessment-report/vokanamet-epar-public-assessment-report_en.pdf
EU-1-13-842,https://www.ema.europa.eu/documents/assessment-report/incresync-epar-public-assessment-report_en.pdf
EU-1-13-841,https://www.ema.europa.eu/documents/assessment-report/spedra-epar-public-assessment-report_en.pdf
EU-1-13-843,https://www.ema.europa.eu/documents/assessment-report/vipdomet-epar-public-assessment-report_en.pdf
EU-1-13-844,https://www.ema.europa.eu/documents/assessment-report/vipidia-epar-public-assessment-report_en.pdf
EU-1-13-862,https://www.ema.europa.eu/documents/assessment-report/ultibro-breezhaler-epar-public-assessment-report_en.pdf
EU-1-13-863,https://www.ema.europa.eu/documents/assessment-report/xoterna-breezhaler-epar-public-assessment-report_en.pdf
EU-1-13-878,https://www.ema.europa.eu/documents/assessment-report/defitelio-epar-public-assessment-report_en.pdf
EU-1-13-865,https://www.ema.europa.eu/documents/assessment-report/tafinlar-epar-public-assessment-report_en.pdf
EU-1-13-904,https://www.ema.europa.eu/documents/assessment-report/mirvaso-epar-public-assessment-report_en.pdf
EU-1-13-858,https://www.ema.europa.eu/documents/assessment-report/stivarga-epar-public-assessment-report_en.pdf
EU-1-13-882,https://www.ema.europa.eu/documents/assessment-report/abilify-maintena-epar-public-assessment-report_en.pdf
EU-1-14-981,https://www.ema.europa.eu/documents/assessment-report/otezla-epar-public-assessment-report_en.pdf
EU-1-14-980,https://www.ema.europa.eu/documents/assessment-report/cosentyx-epar-public-assessment-report_en.pdf
EU-1-13-888,https://www.ema.europa.eu/documents/assessment-report/novoeight-epar-public-assessment-report_en.pdf
EU-1-14-915,https://www.ema.europa.eu/documents/assessment-report/ebilfumin-epar-public-assessment-report_en.pdf
EU-1-13-875,https://www.ema.europa.eu/documents/assessment-report/deltyba-epar-public-assessment-report_en.pdf
EU-1-13-877,https://www.ema.europa.eu/documents/assessment-report/grastofil-epar-public-assessment-report_en.pdf
EU-1-14-913,https://www.ema.europa.eu/documents/assessment-report/latuda-epar-public-assessment-report_en.pdf
EU-1-14-920,https://www.ema.europa.eu/documents/assessment-report/duoresp-spiromax-epar-public-assessment-report_en.pdf
EU-1-13-837,https://www.ema.europa.eu/documents/assessment-report/tecfidera-epar-public-assessment-report_en.pdf
EU-1-13-838,https://www.ema.europa.eu/documents/assessment-report/aubagio-epar-public-assessment-report_en.pdf
EU-1-14-923,https://www.ema.europa.eu/documents/assessment-report/entyvio-epar-public-assessment-report_en.pdf
EU-1-14-929,https://www.ema.europa.eu/documents/assessment-report/revinty-ellipta-epar-public-assessment-report_en.pdf
EU-1-13-901,https://www.ema.europa.eu/documents/assessment-report/sirturo-epar-public-assessment-report_en.pdf
EU-1-14-931,https://www.ema.europa.eu/documents/assessment-report/mekinist-epar-public-assessment-report_en.pdf
EU-1-13-834,https://www.ema.europa.eu/documents/assessment-report/zoledronic-acid-accord-epar-public-assessment-report_en.pdf
EU-1-13-873,https://www.ema.europa.eu/documents/assessment-report/xofigo-epar-public-assessment-report_en.pdf
EU-1-14-969,https://www.ema.europa.eu/documents/assessment-report/scenesse-epar-public-assessment-report_en.pdf
EU-1-13-820,https://www.ema.europa.eu/documents/assessment-report/maruxa-epar-public-assessment-report_en.pdf
EU-1-13-817,https://www.ema.europa.eu/documents/assessment-report/actelsar-hct-epar-public-assessment-report_en.pdf
EU-1-13-832,https://www.ema.europa.eu/documents/assessment-report/stayveer-epar-public-assessment-report_en.pdf
EU-1-13-824,https://www.ema.europa.eu/documents/assessment-report/nemdatine-epar-public-assessment-report_en.pdf
EU-1-13-840,https://www.ema.europa.eu/documents/assessment-report/hyqvia-epar-public-assessment-report_en.pdf
EU-1-13-892,https://www.ema.europa.eu/documents/assessment-report/tivicay-epar-public-assessment-report_en.pdf
EU-1-13-856,https://www.ema.europa.eu/documents/assessment-report/lonquex-epar-public-assessment-report_en.pdf
EU-1-13-829,https://www.ema.europa.eu/documents/assessment-report/hexyon-epar-public-assessment-report_en.pdf
EU-1-13-828,https://www.ema.europa.eu/documents/assessment-report/hexacima-epar-public-assessment-report_en.pdf
EU-1-13-818,https://www.ema.europa.eu/documents/assessment-report/bosulif-epar-public-assessment-report_en.pdf
EU-1-12-811,https://www.ema.europa.eu/documents/assessment-report/lyxumia-epar-public-assessment-report_en.pdf
EU-1-13-879,https://www.ema.europa.eu/documents/assessment-report/giotrif-epar-public-assessment-report_en.pdf
EU-1-13-880,https://www.ema.europa.eu/documents/assessment-report/memantine-accord-epar-public-assessment-report_en.pdf
EU-1-13-881,https://www.ema.europa.eu/documents/assessment-report/lidocaine/prilocaine-plethora-epar-public-assessment-report_en.pdf
EU-1-14-930,https://www.ema.europa.eu/documents/assessment-report/jardiance-epar-public-assessment-report_en.pdf
EU-1-14-943,https://www.ema.europa.eu/documents/assessment-report/velphoro-epar-public-assessment-report_en.pdf
EU-1-12-814,https://www.ema.europa.eu/documents/assessment-report/zaltrap-epar-public-assessment-report_en.pdf
EU-1-13-822,https://www.ema.europa.eu/documents/assessment-report/pheburane-epar-public-assessment-report_en.pdf
EU-1-13-902,https://www.ema.europa.eu/documents/assessment-report/translarna-epar-public-assessment-report_en.pdf
EU-1-14-963,https://www.ema.europa.eu/documents/assessment-report/brimica-genuair-epar-public-assessment-report_en.pdf
EU-1-14-964,https://www.ema.europa.eu/documents/assessment-report/duaklir-genuair-epar-public-assessment-report_en.pdf
EU-1-13-848,https://www.ema.europa.eu/documents/assessment-report/erivedge-epar-public-assessment-report_en.pdf
EU-1-13-860,https://www.ema.europa.eu/documents/assessment-report/nexium-control-epar-public-assessment-report_en.pdf
EU-1-13-861,https://www.ema.europa.eu/documents/assessment-report/procysbi-epar-public-assessment-report_en.pdf
EU-1-13-887,https://www.ema.europa.eu/documents/assessment-report/fluenz-tetra-epar-public-assessment-report_en.pdf
EU-1-13-896,https://www.ema.europa.eu/documents/assessment-report/para-aminosalicylic-acid-lucane-epar-public-assessment-report_en.pdf
EU-1-14-899,https://www.ema.europa.eu/documents/assessment-report/laventair-epar-public-assessment-report_en.pdf
EU-1-13-821,https://www.ema.europa.eu/documents/assessment-report/tolucombi-epar-public-assessment-report_en.pdf
EU-1-13-852,https://www.ema.europa.eu/documents/assessment-report/atosiban-sun-epar-public-assessment-report_en.pdf
EU-1-14-914,https://www.ema.europa.eu/documents/assessment-report/vimizim-epar-public-assessment-report_en.pdf
EU-1-14-940,https://www.ema.europa.eu/documents/assessment-report/triumeq-epar-public-assessment-report_en.pdf
EU-1-14-957,https://www.ema.europa.eu/documents/assessment-report/cyramza-epar-public-assessment-report_en.pdf
EU-1-14-967,https://www.ema.europa.eu/documents/assessment-report/rezolsta-epar-public-assessment-report_en.pdf
EU-1-13-859,https://www.ema.europa.eu/documents/assessment-report/levodopa/carbidopa/entacapone-sandoz-epar-public-assessment-report_en.pdf
EU-1-13-866,https://www.ema.europa.eu/documents/assessment-report/cholib-epar-public-assessment-report_en.pdf
EU-1-14-919,https://www.ema.europa.eu/documents/assessment-report/hemangiol-epar-public-assessment-report_en.pdf
EU-1-14-952,https://www.ema.europa.eu/documents/assessment-report/sevelamer-carbonate-zentiva-epar-public-assessment-report_en.pdf
EU-1-14-954,https://www.ema.europa.eu/documents/assessment-report/vargatef-epar-public-assessment-report_en.pdf
EU-1-14-955,https://www.ema.europa.eu/documents/assessment-report/lymphoseek-epar-public-assessment-report_en.pdf
EU-1-13-855,https://www.ema.europa.eu/documents/assessment-report/imvanex-epar-public-assessment-report_en.pdf
EU-1-14-935,https://www.ema.europa.eu/documents/assessment-report/envarsus-epar-public-assessment-report_en.pdf
EU-1-13-850,https://www.ema.europa.eu/documents/assessment-report/pomalidomide-celgene-epar-public-assessment-report_en.pdf
EU-1-14-974,https://www.ema.europa.eu/documents/assessment-report/cerdelga-epar-public-assessment-report_en.pdf
EU-1-14-975,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-ratiopharm-epar-public-assessment-report_en-0.pdf
EU-1-12-815,https://www.ema.europa.eu/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf
EU-1-13-889,https://www.ema.europa.eu/documents/assessment-report/levetiracetam-hospira-epar-public-assessment-report_en.pdf
EU-1-14-916,https://www.ema.europa.eu/documents/assessment-report/pregabalin-pfizer-epar-public-assessment-report_en.pdf
EU-1-13-823,https://www.ema.europa.eu/documents/assessment-report/adasuve-epar-public-assessment-report_en.pdf
EU-1-13-813,https://www.ema.europa.eu/documents/assessment-report/perjeta-epar-public-assessment-report_en.pdf
EU-1-13-857,https://www.ema.europa.eu/documents/assessment-report/voncento-epar-public-assessment-report_en.pdf
EU-1-13-890,https://www.ema.europa.eu/documents/assessment-report/cometriq-epar-public-assessment-report_en.pdf
EU-1-13-830,https://www.ema.europa.eu/documents/assessment-report/stribild-epar-public-assessment-report_en.pdf
EU-1-13-891,https://www.ema.europa.eu/documents/assessment-report/brintellix-epar-public-assessment-report_en.pdf
EU-1-14-965,https://www.ema.europa.eu/documents/assessment-report/ketoconazole-hra-epar-public-assessment-report_en.pdf
EU-1-13-906,https://www.ema.europa.eu/documents/assessment-report/neuraceq-epar-public-assessment-report_en.pdf
EU-1-14-956,https://www.ema.europa.eu/documents/assessment-report/trulicity-epar-public-assessment-report_en.pdf
EU-1-14-951,https://www.ema.europa.eu/documents/assessment-report/busulfan-fresenius-kabi-epar-public-assessment-report_en.pdf
EU-1-14-970,https://www.ema.europa.eu/documents/assessment-report/rixubis-epar-public-assessment-report_en.pdf
EU-1-14-973,https://www.ema.europa.eu/documents/assessment-report/quinsair-epar-public-assessment-report_en.pdf
EU-1-13-893,https://www.ema.europa.eu/documents/assessment-report/opsumit-epar-public-assessment-report_en.pdf
EU-1-13-826,https://www.ema.europa.eu/documents/assessment-report/memantine-lek-epar-public-assessment-report_en.pdf
EU-1-14-972,https://www.ema.europa.eu/documents/assessment-report/duloxetine-lilly-epar-public-assessment-report_en.pdf
EU-1-14-977,https://www.ema.europa.eu/documents/assessment-report/rasagiline-ratiopharm-epar-public-assessment-report_en.pdf
EU-1-14-978,https://www.ema.europa.eu/documents/assessment-report/senshio-epar-public-assessment-report_en.pdf
EU-1-14-979,https://www.ema.europa.eu/documents/assessment-report/ofev-epar-public-assessment-report_en.pdf
EU-1-13-869,https://www.ema.europa.eu/documents/assessment-report/lemtrada-epar-public-assessment-report_en.pdf
EU-1-14-933,https://www.ema.europa.eu/documents/assessment-report/simbrinza-epar-public-assessment-report_en.pdf
EU-1-14-934,https://www.ema.europa.eu/documents/assessment-report/plegridy-epar-public-assessment-report_en.pdf
EU-1-14-936,https://www.ema.europa.eu/documents/assessment-report/nuwiq-epar-public-assessment-report_en.pdf
EU-1-13-845,https://www.ema.europa.eu/documents/assessment-report/imatinib-accord-epar-public-assessment-report_en.pdf
EU-1-13-846,https://www.ema.europa.eu/documents/assessment-report/xtandi-epar-public-assessment-report_en.pdf
EU-1-13-836,https://www.ema.europa.eu/documents/assessment-report/memantine-ratiopharm-epar-public-assessment-report_en.pdf
EU-1-14-928,https://www.ema.europa.eu/documents/assessment-report/sylvant-epar-public-assessment-report_en.pdf
EU-1-13-853,https://www.ema.europa.eu/documents/assessment-report/remsima-epar-public-assessment-report_en-0.pdf
EU-1-13-854,https://www.ema.europa.eu/documents/assessment-report/inflectra-epar-public-assessment-report_en.pdf
EU-1-14-960,https://www.ema.europa.eu/documents/assessment-report/duavive-epar-public-assessment-report_en.pdf
EU-1-14-961,https://www.ema.europa.eu/documents/assessment-report/tadalafil-mylan-epar-public-assessment-report_en.pdf
EU-1-14-959,https://www.ema.europa.eu/documents/assessment-report/lynparza-epar-public-assessment-report_en.pdf
EU-1-14-958,https://www.ema.europa.eu/documents/assessment-report/harvoni-epar-public-assessment-report_en.pdf
EU-1-13-871,https://www.ema.europa.eu/documents/assessment-report/ovaleap-epar-public-assessment-report_en.pdf
EU-1-13-827,https://www.ema.europa.eu/documents/assessment-report/memantine-mylan-epar-public-assessment-report_en.pdf
EU-1-14-938,https://www.ema.europa.eu/documents/assessment-report/zydelig-epar-public-assessment-report_en.pdf
EU-1-14-947,https://www.ema.europa.eu/documents/assessment-report/xultophy-epar-public-assessment-report_en.pdf
EU-1-13-885,https://www.ema.europa.eu/documents/assessment-report/kadcyla-epar-public-assessment-report_en.pdf
EU-1-13-886,https://www.ema.europa.eu/documents/assessment-report/relvar-ellipta-epar-public-assessment-report_en.pdf
EU-1-13-900,https://www.ema.europa.eu/documents/assessment-report/xigduo-epar-public-assessment-report_en.pdf
EU-1-14-917,https://www.ema.europa.eu/documents/assessment-report/ulunar-breezhaler-epar-public-assessment-report_en.pdf
EU-1-14-921,https://www.ema.europa.eu/documents/assessment-report/biresp-spiromax-epar-public-assessment-report_en.pdf
EU-1-14-937,https://www.ema.europa.eu/documents/assessment-report/gazyvaro-epar-public-assessment-report_en.pdf
EU-1-13-851,https://www.ema.europa.eu/documents/assessment-report/lojuxta-epar-public-assessment-report_en.pdf
EU-1-13-872,https://www.ema.europa.eu/documents/assessment-report/tybost-epar-public-assessment-report_en.pdf
EU-1-13-905,https://www.ema.europa.eu/documents/assessment-report/izba-epar-public-assessment-report_en.pdf
EU-1-13-907,https://www.ema.europa.eu/documents/assessment-report/adempas-epar-public-assessment-report_en.pdf
EU-1-13-909,https://www.ema.europa.eu/documents/assessment-report/bemfola-epar-public-assessment-report_en.pdf
EU-1-14-962,https://www.ema.europa.eu/documents/assessment-report/moventig-epar-public-assessment-report_en.pdf
EU-1-13-835,https://www.ema.europa.eu/documents/assessment-report/voriconazole-accord-epar-public-assessment-report_en.pdf
EU-1-14-941,https://www.ema.europa.eu/documents/assessment-report/vizamyl-epar-public-assessment-report_en.pdf
EU-1-15-999,https://www.ema.europa.eu/documents/assessment-report/zykadia-epar-public-assessment-report_en.pdf
EU-1-15-1009,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-zentiva-epar-public-assessment-report_en.pdf
EU-1-15-1015,https://www.ema.europa.eu/documents/assessment-report/strensiq-epar-public-assessment-report_en.pdf
EU-1-15-1016,https://www.ema.europa.eu/documents/assessment-report/repatha-epar-public-assessment-report_en.pdf
EU-1-15-997,https://www.ema.europa.eu/documents/assessment-report/pregabalin-mylan-epar-public-assessment-report_en.pdf
EU-1-15-1013,https://www.ema.europa.eu/documents/assessment-report/lumark-epar-public-assessment-report_en.pdf
EU-1-15-1010,https://www.ema.europa.eu/documents/assessment-report/duloxetine-mylan-epar-public-assessment-report_en.pdf
EU-1-15-1014,https://www.ema.europa.eu/documents/assessment-report/opdivo-epar-public-assessment-report_en.pdf
EU-1-15-1053,https://www.ema.europa.eu/documents/assessment-report/neofordex-epar-public-assessment-report_en.pdf
EU-1-00-133,https://www.ema.europa.eu/documents/scientific-discussion/optisulin-epar-scientific-discussion_en.pdf
EU-1-15-1005,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-pharmathen-epar-public-assessment-report_en.pdf
EU-1-15-1006,https://www.ema.europa.eu/documents/assessment-report/respreeza-epar-public-assessment-report_en.pdf
EU-1-15-1007,https://www.ema.europa.eu/documents/assessment-report/gardasil-9-epar-public-assessment-report_en.pdf
EU-1-15-1011,https://www.ema.europa.eu/documents/assessment-report/pregabalin-sandoz-epar-public-assessment-report_en.pdf
EU-1-15-1012,https://www.ema.europa.eu/documents/assessment-report/pregabalin-sandoz-gmbh-epar-public-assessment-report_en.pdf
EU-1-15-1000,https://www.ema.europa.eu/documents/assessment-report/jinarc-epar-public-assessment-report_en.pdf
EU-1-15-1001,https://www.ema.europa.eu/documents/assessment-report/akynzeo-epar-public-assessment-report_en.pdf
EU-1-15-1002,https://www.ema.europa.eu/documents/assessment-report/lenvima-epar-public-assessment-report_en.pdf
EU-1-15-1003,https://www.ema.europa.eu/documents/assessment-report/synjardy-epar-public-assessment-report_en.pdf
EU-1-15-1018,https://www.ema.europa.eu/documents/assessment-report/omidria-epar-public-assessment-report_en.pdf
EU-1-15-1019,https://www.ema.europa.eu/documents/assessment-report/bortezomib-accord-epar-public-assessment-report_en.pdf
EU-1-15-1020,https://www.ema.europa.eu/documents/assessment-report/raxone-epar-public-assessment-report_en.pdf
EU-1-15-1043,https://www.ema.europa.eu/documents/assessment-report/nucala-epar-public-assessment-report_en.pdf
EU-1-15-1045,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-accord-epar-public-assessment-report_en.pdf
EU-1-15-1046,https://www.ema.europa.eu/documents/assessment-report/elocta-epar-public-assessment-report_en.pdf
EU-1-15-1047,https://www.ema.europa.eu/documents/assessment-report/blincyto-epar-public-assessment-report_en.pdf
EU-1-15-1048,https://www.ema.europa.eu/documents/assessment-report/cotellic-epar-public-assessment-report_en.pdf
EU-1-15-1049,https://www.ema.europa.eu/documents/assessment-report/cystadrops-epar-public-assessment-report_en.pdf
EU-1-15-1051,https://www.ema.europa.eu/documents/assessment-report/ebymect-epar-public-assessment-report_en.pdf
EU-1-15-1052,https://www.ema.europa.eu/documents/assessment-report/edistride-epar-public-assessment-report_en.pdf
EU-1-14-984,https://www.ema.europa.eu/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf
EU-1-15-989,https://www.ema.europa.eu/documents/assessment-report/tenkasi-previously-orbactiv-epar-public-assessment-report_en.pdf
EU-1-15-1008,https://www.ema.europa.eu/documents/assessment-report/hetlioz-epar-public-assessment-report_en.pdf
EU-1-10-615,https://www.ema.europa.eu/documents/assessment-report/temozolomide-hospira-epar-public-assessment-report_en.pdf
EU-1-16-1097,https://www.ema.europa.eu/documents/assessment-report/strimvelis-epar-public-assessment-report_en.pdf
EU-1-15-1067,https://www.ema.europa.eu/documents/assessment-report/lopinavir/ritonavir-mylan-epar-public-assessment-report_en.pdf
EU-1-15-1061,https://www.ema.europa.eu/documents/assessment-report/genvoya-epar-public-assessment-report_en.pdf
EU-1-15-1065,https://www.ema.europa.eu/documents/assessment-report/eptifibatide-accord-epar-public-assessment-report_en.pdf
EU-1-15-991,https://www.ema.europa.eu/documents/assessment-report/sivextro-epar-public-assessment-report_en.pdf
EU-1-14-986,https://www.ema.europa.eu/documents/assessment-report/xydalba-epar-public-assessment-report_en.pdf
EU-1-14-987,https://www.ema.europa.eu/documents/assessment-report/holoclar-epar-public-assessment-report_en.pdf
EU-1-15-994,https://www.ema.europa.eu/documents/assessment-report/kengrexal-epar-public-assessment-report_en.pdf
EU-1-15-1071,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-accord-epar-public-assessment-report_en.pdf
EU-1-15-1072,https://www.ema.europa.eu/documents/assessment-report/spectrila-epar-public-assessment-report_en.pdf
EU-1-15-1073,https://www.ema.europa.eu/documents/assessment-report/briviact-epar-public-assessment-report_en.pdf
EU-1-16-1092,https://www.ema.europa.eu/documents/assessment-report/amlodipine/valsartan-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1103,https://www.ema.europa.eu/documents/assessment-report/neparvis-epar-public-assessment-report_en.pdf
EU-1-15-1055,https://www.ema.europa.eu/documents/assessment-report/ciambra-epar-public-assessment-report_en.pdf
EU-1-16-1098,https://www.ema.europa.eu/documents/assessment-report/alprolix-epar-public-assessment-report_en.pdf
EU-1-15-1036,https://www.ema.europa.eu/documents/assessment-report/cresemba-epar-public-assessment-report_en.pdf
EU-1-16-1102,https://www.ema.europa.eu/documents/assessment-report/bortezomib-sun-epar-public-assessment-report_en.pdf
EU-1-14-944,https://www.ema.europa.eu/documents/assessment-report/abasria-epar-public-assessment-report_en.pdf
EU-1-15-1031,https://www.ema.europa.eu/documents/assessment-report/praluent-epar-public-assessment-report_en.pdf
EU-1-15-1032,https://www.ema.europa.eu/documents/assessment-report/zerbaxa-epar-public-assessment-report_en.pdf
EU-1-15-1058,https://www.ema.europa.eu/documents/assessment-report/entresto-epar-public-assessment-report_en.pdf
EU-1-15-1059,https://www.ema.europa.eu/documents/assessment-report/orkambi-epar-public-assessment-report_en.pdf
EU-1-15-1060,https://www.ema.europa.eu/documents/assessment-report/kyprolis-epar-public-assessment-report_en.pdf
EU-1-15-1074,https://www.ema.europa.eu/documents/assessment-report/benepali-epar-public-assessment-report_en.pdf
EU-1-15-1064,https://www.ema.europa.eu/documents/assessment-report/imlygic-epar-public-assessment-report_en.pdf
EU-1-16-1099,https://www.ema.europa.eu/documents/assessment-report/descovy-epar-public-assessment-report_en.pdf
EU-1-15-1029,https://www.ema.europa.eu/documents/assessment-report/aripiprazole-sandoz-epar-public-assessment-report_en.pdf
EU-1-15-1068,https://www.ema.europa.eu/documents/assessment-report/wakix-epar-public-assessment-report_en.pdf
EU-1-15-1040,https://www.ema.europa.eu/documents/assessment-report/intuniv-epar-public-assessment-report_en.pdf
EU-1-15-1041,https://www.ema.europa.eu/documents/assessment-report/ivabradine-anpharm-epar-public-assessment-report_en.pdf
EU-1-16-1094,https://www.ema.europa.eu/documents/assessment-report/ninlaro-epar-public-assessment-report_en.pdf
EU-1-16-1087,https://www.ema.europa.eu/documents/assessment-report/coagadex-epar-public-assessment-report_en.pdf
EU-1-16-1088,https://www.ema.europa.eu/documents/assessment-report/empliciti-epar-public-assessment-report_en.pdf
EU-1-16-1093,https://www.ema.europa.eu/documents/assessment-report/zonisamide-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1090,https://www.ema.europa.eu/documents/assessment-report/rasagiline-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1096,https://www.ema.europa.eu/documents/assessment-report/lonsurf-epar-public-assessment-report_en.pdf
EU-1-14-988,https://www.ema.europa.eu/documents/assessment-report/mysimba-epar-public-assessment-report_en.pdf
EU-1-15-1063,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-actavis-epar-public-assessment-report_en.pdf
EU-1-15-992,https://www.ema.europa.eu/documents/assessment-report/saxenda-epar-public-assessment-report_en.pdf
EU-1-15-993,https://www.ema.europa.eu/documents/assessment-report/lixiana-epar-public-assessment-report_en.pdf
EU-1-16-1091,https://www.ema.europa.eu/documents/assessment-report/atazanavir-mylan-epar-public-assessment-report_en.pdf
EU-1-15-1027,https://www.ema.europa.eu/documents/assessment-report/pregabalin-accord-epar-public-assessment-report_en.pdf
EU-1-15-1028,https://www.ema.europa.eu/documents/assessment-report/duloxetine-zentiva-epar-public-assessment-report_en.pdf
EU-1-15-1037,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-sandoz-epar-public-assessment-report_en.pdf
EU-1-15-1038,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-medac-epar-public-assessment-report_en.pdf
EU-1-15-1030,https://www.ema.europa.eu/documents/assessment-report/odomzo-epar-public-assessment-report_en.pdf
EU-1-15-1083,https://www.ema.europa.eu/documents/assessment-report/uptravi-epar-public-assessment-report_en.pdf
EU-1-16-1095,https://www.ema.europa.eu/documents/assessment-report/idelvion-epar-public-assessment-report_en.pdf
EU-1-15-1024,https://www.ema.europa.eu/documents/assessment-report/keytruda-epar-public-assessment-report_en.pdf
EU-1-15-1054,https://www.ema.europa.eu/documents/assessment-report/cinacalcet-mylan-epar-public-assessment-report_en.pdf
EU-1-15-1082,https://www.ema.europa.eu/documents/assessment-report/galafold-epar-public-assessment-report_en.pdf
EU-1-15-1066,https://www.ema.europa.eu/documents/assessment-report/ongentys-epar-public-assessment-report_en.pdf
EU-1-15-990,https://www.ema.europa.eu/documents/assessment-report/ikervis-epar-public-assessment-report_en.pdf
EU-1-15-1070,https://www.ema.europa.eu/documents/assessment-report/oncaspar-epar-public-assessment-report_en.pdf
EU-1-15-1021,https://www.ema.europa.eu/documents/assessment-report/pregabalin-zentiva-epar-public-assessment-report_en.pdf
EU-1-15-1023,https://www.ema.europa.eu/documents/assessment-report/farydak-epar-public-assessment-report_en.pdf
EU-1-15-1085,https://www.ema.europa.eu/documents/assessment-report/taltz-epar-public-assessment-report_en.pdf
EU-1-16-1101,https://www.ema.europa.eu/documents/assessment-report/darzalex-epar-public-assessment-report_en.pdf
EU-1-15-1075,https://www.ema.europa.eu/documents/assessment-report/feraccru-epar-public-assessment-report_en.pdf
EU-1-15-1079,https://www.ema.europa.eu/documents/assessment-report/vaxelis-epar-public-assessment-report_en.pdf
EU-1-15-1062,https://www.ema.europa.eu/documents/assessment-report/ravicti-epar-public-assessment-report_en.pdf
EU-1-14-982,https://www.ema.europa.eu/documents/assessment-report/viekirax-epar-public-assessment-report_en.pdf
EU-1-14-983,https://www.ema.europa.eu/documents/assessment-report/exviera-epar-public-assessment-report_en.pdf
EU-1-16-1104,https://www.ema.europa.eu/documents/assessment-report/palonosetron-accord-epar-public-assessment-report_en.pdf
EU-1-15-1033,https://www.ema.europa.eu/documents/assessment-report/kanuma-epar-public-assessment-report_en.pdf
EU-1-16-1119,https://www.ema.europa.eu/documents/assessment-report/zepatier-epar-public-assessment-report_en.pdf
EU-1-16-1125,https://www.ema.europa.eu/documents/assessment-report/cinqaero-epar-public-assessment-report_en.pdf
EU-1-16-1152,https://www.ema.europa.eu/documents/assessment-report/roteas-epar-public-assessment-report_en.pdf
EU-1-17-1182,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-krka-dd-epar-public-assessment-report_en.pdf
EU-1-17-1184,https://www.ema.europa.eu/documents/assessment-report/riximyo-epar-public-assessment-report_en.pdf
EU-1-17-1187,https://www.ema.europa.eu/documents/assessment-report/trumenba-epar-public-assessment-report_en.pdf
EU-1-17-1197,https://www.ema.europa.eu/documents/assessment-report/oxervate-epar-public-assessment-report_en.pdf
EU-1-17-1234,https://www.ema.europa.eu/documents/assessment-report/tremfya-epar-public-assessment-report_en.pdf
EU-1-17-1255,https://www.ema.europa.eu/documents/assessment-report/intrarosa-epar-public-assessment-report_en.pdf
EU-1-17-1229,https://www.ema.europa.eu/documents/assessment-report/dupixent-epar-public-assessment-report_en.pdf
EU-1-17-1230,https://www.ema.europa.eu/documents/assessment-report/lacosamide-accord-epar-public-assessment-report_en.pdf
EU-1-17-1262,https://www.ema.europa.eu/documents/assessment-report/crysvita-epar-public-assessment-report_en.pdf
EU-1-16-1124,https://www.ema.europa.eu/documents/assessment-report/nordimet-epar-public-assessment-report_en.pdf
EU-1-16-1141,https://www.ema.europa.eu/documents/assessment-report/somakit-toc-epar-public-assessment-report_en.pdf
EU-1-16-1146,https://www.ema.europa.eu/documents/assessment-report/glyxambi-epar-public-assessment-report_en.pdf
EU-1-16-1147,https://www.ema.europa.eu/documents/assessment-report/ibrance-epar-public-assessment-report_en.pdf
EU-1-17-1215,https://www.ema.europa.eu/documents/assessment-report/fotivda-epar-public-assessment-report_en.pdf
EU-1-17-1216,https://www.ema.europa.eu/documents/assessment-report/imraldi-epar-public-assessment-report_en.pdf
EU-1-17-1218,https://www.ema.europa.eu/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf
EU-1-16-1110,https://www.ema.europa.eu/documents/assessment-report/chenodeoxycholic-acid-sigma-tau-epar-public-assessment-report_en.pdf
EU-1-17-1212,https://www.ema.europa.eu/documents/assessment-report/mavenclad-epar-public-assessment-report_en.pdf
EU-1-17-1222,https://www.ema.europa.eu/documents/assessment-report/efavirenz/emtricitabine/tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1134,https://www.ema.europa.eu/documents/assessment-report/mysildecard-epar-public-assessment-report_en.pdf
EU-1-16-1137,https://www.ema.europa.eu/documents/assessment-report/granpidam-epar-public-assessment-report_en.pdf
EU-1-16-1140,https://www.ema.europa.eu/documents/assessment-report/darunavir-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1148,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-zentiva-epar-public-assessment-report_en.pdf
EU-1-16-1132,https://www.ema.europa.eu/documents/assessment-report/inhixa-epar-public-assessment-report_en.pdf
EU-1-16-1142,https://www.ema.europa.eu/documents/assessment-report/parsabiv-epar-public-assessment-report_en.pdf
EU-1-16-1127,https://www.ema.europa.eu/documents/assessment-report/tenofovir-disoproxil-zentiva-epar-public-assessment-report_en.pdf
EU-1-16-1105,https://www.ema.europa.eu/documents/assessment-report/endolucinbeta-epar-public-assessment-report_en.pdf
EU-1-16-1114,https://www.ema.europa.eu/documents/assessment-report/bortezomib-hospira-epar-public-assessment-report_en.pdf
EU-1-16-1154,https://www.ema.europa.eu/documents/assessment-report/vemlidy-epar-public-assessment-report_en.pdf
EU-1-16-1160,https://www.ema.europa.eu/documents/assessment-report/fiasp-epar-public-assessment-report_en.pdf
EU-1-16-1161,https://www.ema.europa.eu/documents/assessment-report/movymia-epar-public-assessment-report_en.pdf
EU-1-17-1178,https://www.ema.europa.eu/documents/assessment-report/xeljanz-epar-public-assessment-report_en.pdf
EU-1-16-1151,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-krka-epar-public-assessment-report_en.pdf
EU-1-17-1172,https://www.ema.europa.eu/documents/assessment-report/jylamvo-epar-public-assessment-report_en.pdf
EU-1-17-1214,https://www.ema.europa.eu/documents/assessment-report/bavencio-epar-public-assessment-report_en.pdf
EU-1-16-1153,https://www.ema.europa.eu/documents/assessment-report/tadalafil-generics-epar-public-assessment-report_en.pdf
EU-1-16-1128,https://www.ema.europa.eu/documents/assessment-report/kisplyx-epar-public-assessment-report_en.pdf
EU-1-16-1144,https://www.ema.europa.eu/documents/assessment-report/ivabradine-zentiva-epar-public-assessment-report_en.pdf
EU-1-16-1116,https://www.ema.europa.eu/documents/assessment-report/epclusa-epar-public-assessment-report_en.pdf
EU-1-17-1193,https://www.ema.europa.eu/documents/assessment-report/refixia-epar-public-assessment-report_en.pdf
EU-1-17-1199,https://www.ema.europa.eu/documents/assessment-report/cuprior-epar-public-assessment-report_en.pdf
EU-1-17-1200,https://www.ema.europa.eu/documents/assessment-report/besponsa-epar-public-assessment-report_en.pdf
EU-1-17-1201,https://www.ema.europa.eu/documents/assessment-report/skilarence-epar-public-assessment-report_en.pdf
EU-1-17-1211,https://www.ema.europa.eu/documents/assessment-report/entecavir-accord-epar-public-assessment-report_en.pdf
EU-1-17-1223,https://www.ema.europa.eu/documents/assessment-report/vosevi-epar-public-assessment-report_en.pdf
EU-1-17-1227,https://www.ema.europa.eu/documents/assessment-report/entecavir-mylan-epar-public-assessment-report_en.pdf
EU-1-17-1195,https://www.ema.europa.eu/documents/assessment-report/erelzi-epar-public-assessment-report_en.pdf
EU-1-17-1196,https://www.ema.europa.eu/documents/assessment-report/kevzara-epar-public-assessment-report_en.pdf
EU-1-17-1225,https://www.ema.europa.eu/documents/assessment-report/symtuza-epar-public-assessment-report_en.pdf
EU-1-17-1228,https://www.ema.europa.eu/documents/assessment-report/tookad-epar-public-assessment-report_en.pdf
EU-1-18-1265,https://www.ema.europa.eu/documents/assessment-report/segluromet-epar-public-assessment-report_en.pdf
EU-1-18-1266,https://www.ema.europa.eu/documents/assessment-report/steglujan-epar-public-assessment-report_en.pdf
EU-1-18-1267,https://www.ema.europa.eu/documents/assessment-report/steglatro-epar-public-assessment-report_en.pdf
EU-1-18-1270,https://www.ema.europa.eu/documents/assessment-report/semglee-epar-public-assessment-report_en.pdf
EU-1-18-1276,https://www.ema.europa.eu/documents/assessment-report/myalepta-epar-public-assessment-report_en.pdf
EU-1-17-1219,https://www.ema.europa.eu/documents/assessment-report/verkazia-epar-public-assessment-report_en.pdf
EU-1-17-1220,https://www.ema.europa.eu/documents/assessment-report/tecentriq-epar-public-assessment-report_en.pdf
EU-1-17-1221,https://www.ema.europa.eu/documents/assessment-report/kisqali-epar-public-assessment-report_en.pdf
EU-1-17-1236,https://www.ema.europa.eu/documents/assessment-report/trelegy-ellipta-epar-public-assessment-report_en.pdf
EU-1-17-1237,https://www.ema.europa.eu/documents/assessment-report/elebrato-ellipta-epar-public-assessment-report_en.pdf
EU-1-17-1238,https://www.ema.europa.eu/documents/assessment-report/nyxoid-epar-public-assessment-report_en.pdf
EU-1-16-1168,https://www.ema.europa.eu/documents/assessment-report/vihuma-epar-public-assessment-report_en.pdf
EU-1-17-1175,https://www.ema.europa.eu/documents/assessment-report/daptomycin-hospira-epar-public-assessment-report_en.pdf
EU-1-16-1169,https://www.ema.europa.eu/documents/assessment-report/alecensa-epar-public-assessment-report_en.pdf
EU-1-16-1133,https://www.ema.europa.eu/documents/assessment-report/emtricitabine/tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf
EU-1-17-1188,https://www.ema.europa.eu/documents/assessment-report/spinraza-epar-public-assessment-report_en.pdf
EU-1-17-1173,https://www.ema.europa.eu/documents/assessment-report/lokelma-epar-public-assessment-report_en.pdf
EU-1-17-1205,https://www.ema.europa.eu/documents/assessment-report/blitzima-epar-public-assessment-report_en.pdf
EU-1-17-1226,https://www.ema.europa.eu/documents/assessment-report/lutathera-epar-public-assessment-report_en.pdf
EU-1-16-1106,https://www.ema.europa.eu/documents/assessment-report/flixabi-epar-public-assessment-report_en.pdf
EU-1-16-1108,https://www.ema.europa.eu/documents/assessment-report/qtern-epar-public-assessment-report_en.pdf
EU-1-16-1109,https://www.ema.europa.eu/documents/assessment-report/zavicefta-epar-public-assessment-report_en.pdf
EU-1-16-1155,https://www.ema.europa.eu/documents/assessment-report/kyntheum-epar-public-assessment-report_en.pdf
EU-1-16-1157,https://www.ema.europa.eu/documents/assessment-report/suliqua-epar-public-assessment-report_en.pdf
EU-1-17-1176,https://www.ema.europa.eu/documents/assessment-report/yargesa-epar-public-assessment-report_en.pdf
EU-1-16-1138,https://www.ema.europa.eu/documents/assessment-report/venclyxto-epar-public-assessment-report_en.pdf
EU-1-16-1164,https://www.ema.europa.eu/documents/assessment-report/amgevita-epar-public-assessment-report_en.pdf
EU-1-17-1194,https://www.ema.europa.eu/documents/assessment-report/febuxostat-mylan-epar-public-assessment-report_en.pdf
EU-1-17-1203,https://www.ema.europa.eu/documents/assessment-report/insulin-lispro-sanofi-epar-public-assessment-report_en.pdf
EU-1-17-1202,https://www.ema.europa.eu/documents/assessment-report/ucedane-epar-public-assessment-report_en.pdf
EU-1-17-1224,https://www.ema.europa.eu/documents/assessment-report/xermelo-epar-public-assessment-report_en.pdf
EU-1-17-1251,https://www.ema.europa.eu/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf
EU-1-16-1150,https://www.ema.europa.eu/documents/assessment-report/rekovelle-epar-public-assessment-report_en.pdf
EU-1-16-1158,https://www.ema.europa.eu/documents/assessment-report/afstyla-epar-public-assessment-report_en.pdf
EU-1-16-1159,https://www.ema.europa.eu/documents/assessment-report/terrosa-epar-public-assessment-report_en.pdf
EU-1-17-1179,https://www.ema.europa.eu/documents/assessment-report/veltassa-epar-public-assessment-report_en.pdf
EU-1-17-1213,https://www.ema.europa.eu/documents/assessment-report/maviret-epar-public-assessment-report_en.pdf
EU-1-16-1112,https://www.ema.europa.eu/documents/assessment-report/odefsey-epar-public-assessment-report_en.pdf
EU-1-16-1129,https://www.ema.europa.eu/documents/assessment-report/tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1135,https://www.ema.europa.eu/documents/assessment-report/sialanar-epar-public-assessment-report_en.pdf
EU-1-17-1185,https://www.ema.europa.eu/documents/assessment-report/rixathon-epar-public-assessment-report_en.pdf
EU-1-17-1210,https://www.ema.europa.eu/documents/assessment-report/efavirenz/emtricitabine/tenofovir-disoproxil-zentiva-epar-public-assessment-report_en.pdf
EU-1-17-1253,https://www.ema.europa.eu/documents/assessment-report/fulvestrant-mylan-epar-public-assessment-report_en.pdf
EU-1-17-1256,https://www.ema.europa.eu/documents/assessment-report/anagrelide-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1156,https://www.ema.europa.eu/documents/assessment-report/zinplava-epar-public-assessment-report_en.pdf
EU-1-17-1177,https://www.ema.europa.eu/documents/assessment-report/tadalafil-lilly-epar-public-assessment-report_en.pdf
EU-1-17-1181,https://www.ema.europa.eu/documents/assessment-report/spherox-epar-public-assessment-report_en.pdf
EU-1-17-1232,https://www.ema.europa.eu/documents/assessment-report/miglustat-genorph-epar-public-assessment-report_en.pdf
EU-1-17-1233,https://www.ema.europa.eu/documents/assessment-report/zubsolv-epar-public-assessment-report_en.pdf
EU-1-17-1235,https://www.ema.europa.eu/documents/assessment-report/zejula-epar-public-assessment-report_en.pdf
EU-1-16-1166,https://www.ema.europa.eu/documents/assessment-report/pregabalin-zentiva-ks-epar-public-assessment-report_en.pdf
EU-1-16-1170,https://www.ema.europa.eu/documents/assessment-report/olumiant-epar-public-assessment-report_en.pdf
EU-1-16-1171,https://www.ema.europa.eu/documents/assessment-report/ledaga-epar-public-assessment-report_en.pdf
EU-1-17-1244,https://www.ema.europa.eu/documents/assessment-report/tacforius-epar-public-assessment-report_en.pdf
EU-1-17-1263,https://www.ema.europa.eu/documents/assessment-report/efavirenz/emtricitabine/tenofovir-disoproxil-krka-epar-public-assessment-report_en.pdf
EU-1-18-1274,https://www.ema.europa.eu/documents/assessment-report/trydonis-epar-public-assessment-report_en.pdf
EU-1-18-1275,https://www.ema.europa.eu/documents/assessment-report/riarify-previously-chf-5993-chiesi-farmaceutici-spa-epar-public-assessment-report_en.pdf
EU-1-17-1239,https://www.ema.europa.eu/documents/assessment-report/veraseal-epar-public-assessment-report_en.pdf
EU-1-17-1245,https://www.ema.europa.eu/documents/assessment-report/prevymis-epar-public-assessment-report_en.pdf
EU-1-17-1246,https://www.ema.europa.eu/documents/assessment-report/mvasi-epar-public-assessment-report_en.pdf
EU-1-17-1250,https://www.ema.europa.eu/documents/assessment-report/rubraca-epar-public-assessment-report_en.pdf
EU-1-17-1258,https://www.ema.europa.eu/documents/assessment-report/lamzede-epar-public-assessment-report_en.pdf
EU-1-17-1260,https://www.ema.europa.eu/documents/assessment-report/alkindi-epar-public-assessment-report_en.pdf
EU-1-17-1261,https://www.ema.europa.eu/documents/assessment-report/alofisel-epar-public-assessment-report_en.pdf
EU-1-17-1190,https://www.ema.europa.eu/documents/assessment-report/ivabradine-accord-epar-public-assessment-report_en.pdf
EU-1-17-1254,https://www.ema.europa.eu/documents/assessment-report/jorveza-epar-public-assessment-report_en.pdf
EU-1-17-1208,https://www.ema.europa.eu/documents/assessment-report/trimbow-epar-public-assessment-report_en.pdf
EU-1-16-1089,https://www.ema.europa.eu/documents/assessment-report/pandemic-influenza-vaccine-h5n1-medimmune-epar-public-assessment-report_en.pdf
EU-1-17-1231,https://www.ema.europa.eu/documents/assessment-report/ocrevus-epar-public-assessment-report_en.pdf
EU-1-17-1241,https://www.ema.europa.eu/documents/assessment-report/ontruzant-epar-public-assessment-report_en-0.pdf
EU-1-17-1242,https://www.ema.europa.eu/documents/assessment-report/ritonavir-mylan-epar-public-assessment-report_en.pdf
EU-1-17-1186,https://www.ema.europa.eu/documents/assessment-report/axumin-epar-public-assessment-report_en.pdf
EU-1-18-1264,https://www.ema.europa.eu/documents/assessment-report/alunbrig-epar-public-assessment-report_en.pdf
EU-1-18-1271,https://www.ema.europa.eu/documents/assessment-report/hemlibra-epar-public-assessment-report_en.pdf
EU-1-18-1272,https://www.ema.europa.eu/documents/assessment-report/shingrix-epar-public-assessment-report_en.pdf
EU-1-15-1004,https://www.ema.europa.eu/documents/assessment-report/voriconazole-hospira-epar-public-assessment-report_en.pdf
EU-1-17-1209,https://www.ema.europa.eu/documents/assessment-report/reagila-epar-public-assessment-report_en.pdf
EU-1-17-1249,https://www.ema.europa.eu/documents/assessment-report/darunavir-krka-epar-public-assessment-report_en.pdf
EU-1-17-1252,https://www.ema.europa.eu/documents/assessment-report/fasenra-epar-public-assessment-report_en.pdf
EU-1-16-1167,https://www.ema.europa.eu/documents/assessment-report/truxima-epar-public-assessment-report_en.pdf
EU-1-17-1247,https://www.ema.europa.eu/documents/assessment-report/adynovi-epar-public-assessment-report_en.pdf
EU-1-18-1269,https://www.ema.europa.eu/documents/assessment-report/alpivab-epar-public-assessment-report_en.pdf
EU-1-16-1115,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-fresenius-kabi-epar-public-assessment-report_en.pdf
EU-1-16-1136,https://www.ema.europa.eu/documents/assessment-report/cabometyx-epar-public-assessment-report_en.pdf
EU-1-17-1192,https://www.ema.europa.eu/documents/assessment-report/brineura-epar-public-assessment-report_en.pdf
EU-1-17-1217,https://www.ema.europa.eu/documents/assessment-report/nitisinone-mendelikabs-epar-public-assessment-report_en.pdf
EU-1-18-1278,https://www.ema.europa.eu/documents/assessment-report/carmustine-obvius-epar-public-assessment-report_en.pdf
EU-1-18-1279,https://www.ema.europa.eu/documents/assessment-report/amglidia-epar-public-assessment-report_en.pdf
EU-1-18-1277,https://www.ema.europa.eu/documents/assessment-report/mylotarg-epar-public-assessment-report_en.pdf
EU-1-18-1281,https://www.ema.europa.eu/documents/assessment-report/kanjinti-epar-public-assessment-report_en.pdf
EU-1-18-1282,https://www.ema.europa.eu/documents/assessment-report/juluca-epar-public-assessment-report_en.pdf
EU-1-18-1280,https://www.ema.europa.eu/documents/assessment-report/zessly-epar-public-assessment-report_en.pdf
EU-1-18-1283,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-krka-epar-public-assessment-report_en.pdf
EU-1-19-1410,https://www.ema.europa.eu/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf
EU-1-20-1459,https://www.ema.europa.eu/documents/assessment-report/veklury-epar-public-assessment-report_en.pdf
EU-1-19-1404,https://www.ema.europa.eu/documents/assessment-report/rinvoq-epar-public-assessment-report_en.pdf
EU-1-19-1405,https://www.ema.europa.eu/documents/assessment-report/tavlesse-epar-public-assessment-report_en.pdf
EU-1-19-1392,https://www.ema.europa.eu/documents/assessment-report/ervebo-epar-public-assessment-report_en.pdf
EU-1-19-1393,https://www.ema.europa.eu/documents/assessment-report/quofenix-epar-public-assessment-report_en.pdf
EU-1-20-1447,https://www.ema.europa.eu/documents/assessment-report/insulin-aspart-sanofi-epar-public-assessment-report_en.pdf
EU-1-19-1396,https://www.ema.europa.eu/documents/assessment-report/ivozall-epar-public-assessment-report_en.pdf
EU-1-19-1397,https://www.ema.europa.eu/documents/assessment-report/bortezomib-fresenius-kabi-epar-public-assessment-report_en.pdf
EU-1-20-1460,https://www.ema.europa.eu/documents/assessment-report/rozlytrek-epar-public-assessment-report_en.pdf
EU-1-20-1474,https://www.ema.europa.eu/documents/assessment-report/blenrep-epar-public-assessment-report_en-0.pdf
EU-1-20-1475,https://www.ema.europa.eu/documents/assessment-report/arsenic-trioxide-medac-epar-public-assessment-report_en.pdf
EU-1-20-1476,https://www.ema.europa.eu/documents/assessment-report/adakveo-epar-public-assessment-report_en.pdf
EU-1-19-1371,https://www.ema.europa.eu/documents/assessment-report/ultomiris-epar-public-assessment-report_en.pdf
EU-1-19-1372,https://www.ema.europa.eu/documents/assessment-report/striascan-epar-public-assessment-report_en.pdf
EU-1-19-1373,https://www.ema.europa.eu/documents/assessment-report/doptelet-epar-public-assessment-report_en.pdf
EU-1-19-1374,https://www.ema.europa.eu/documents/assessment-report/esperoct-epar-public-assessment-report_en.pdf
EU-1-19-1375,https://www.ema.europa.eu/documents/assessment-report/grasustek-epar-public-assessment-report_en.pdf
EU-1-19-1376,https://www.ema.europa.eu/documents/assessment-report/libtayo-epar-public-assessment-report_en.pdf
EU-1-19-1356,https://www.ema.europa.eu/documents/assessment-report/idacio-epar-public-assessment-report_en.pdf
EU-1-19-1365,https://www.ema.europa.eu/documents/assessment-report/cufence-epar-public-assessment-report_en.pdf
EU-1-19-1377,https://www.ema.europa.eu/documents/assessment-report/talzenna-epar-public-assessment-report_en.pdf
EU-1-19-1370,https://www.ema.europa.eu/documents/assessment-report/dovato-epar-public-assessment-report_en.pdf
EU-1-20-1450,https://www.ema.europa.eu/documents/assessment-report/fingolimod-accord-epar-public-assessment-report_en.pdf
EU-1-18-1334,https://www.ema.europa.eu/documents/assessment-report/vabomere-epar-public-assessment-report_en.pdf
EU-1-17-1174,https://www.ema.europa.eu/documents/assessment-report/rolufta-epar-public-assessment-report_en.pdf
EU-1-20-1454,https://www.ema.europa.eu/documents/assessment-report/aybintio-epar-public-assessment-report_en.pdf
EU-1-20-1455,https://www.ema.europa.eu/documents/assessment-report/piqray-epar-public-assessment-report_en.pdf
EU-1-20-1456,https://www.ema.europa.eu/documents/assessment-report/zercepac-epar-public-assessment-report_en.pdf
EU-1-19-1368,https://www.ema.europa.eu/documents/assessment-report/ambrisentan-mylan-epar-public-assessment-report_en.pdf
EU-1-19-1408,https://www.ema.europa.eu/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf
EU-1-20-1473,https://www.ema.europa.eu/documents/assessment-report/ayvakyt-epar-public-assessment-report_en.pdf
EU-1-19-1364,https://www.ema.europa.eu/documents/assessment-report/nuceiva-epar-public-assessment-report_en.pdf
EU-1-20-1471,https://www.ema.europa.eu/documents/assessment-report/idefirix-epar-public-assessment-report_en.pdf
EU-1-19-1366,https://www.ema.europa.eu/documents/assessment-report/xromi-epar-public-assessment-report_en.pdf
EU-1-19-1400,https://www.ema.europa.eu/documents/assessment-report/rhokiinsa-epar-public-assessment-report_en.pdf
EU-1-19-1406,https://www.ema.europa.eu/documents/assessment-report/baqsimi-epar-public-assessment-report_en.pdf
EU-1-20-1462,https://www.ema.europa.eu/documents/assessment-report/livogiva-epar-public-assessment-report_en.pdf
EU-1-19-1411,https://www.ema.europa.eu/documents/assessment-report/evenity-epar-public-assessment-report_en.pdf
EU-1-20-1465,https://www.ema.europa.eu/documents/assessment-report/gencebok-epar-public-assessment-report_en.pdf
EU-1-20-1451,https://www.ema.europa.eu/documents/assessment-report/daurismo-epar-public-assessment-report_en.pdf
EU-1-20-1452,https://www.ema.europa.eu/documents/assessment-report/reblozyl-epar-public-assessment-report_en.pdf
EU-1-20-1468,https://www.ema.europa.eu/documents/assessment-report/kaftrio-epar-public-assessment-report_en.pdf
EU-1-19-1362,https://www.ema.europa.eu/documents/assessment-report/palynziq-epar-public-assessment-report_en.pdf
EU-1-20-1480,https://www.ema.europa.eu/documents/assessment-report/jyseleca-epar-public-assessment-report_en.pdf
EU-1-18-1292,https://www.ema.europa.eu/documents/assessment-report/apealea-epar-public-assessment-report_en.pdf
EU-1-19-1398,https://www.ema.europa.eu/documents/assessment-report/arsenic-trioxide-accord-epar-public-assessment-report_en.pdf
EU-1-20-1448,https://www.ema.europa.eu/documents/assessment-report/cabazitaxel-accord-epar-public-assessment-report_en.pdf
EU-1-19-1409,https://www.ema.europa.eu/documents/assessment-report/pegfilgrastim-mundipharma-epar-public-assessment-report_en.pdf
EU-1-20-1469,https://www.ema.europa.eu/documents/assessment-report/arikayce-liposomal-epar-public-assessment-report_en.pdf
EU-1-19-1395,https://www.ema.europa.eu/documents/assessment-report/clopidogrel/acetylsalicylic-acid-mylan-epar-public-assessment-report_en.pdf
EU-1-19-1361,https://www.ema.europa.eu/documents/assessment-report/skyrizi-epar-public-assessment-report_en.pdf
EU-1-19-1385,https://www.ema.europa.eu/documents/assessment-report/vitrakvi-epar-public-assessment-report_en.pdf
EU-1-19-1386,https://www.ema.europa.eu/documents/assessment-report/deferasirox-mylan-epar-public-assessment-report_en.pdf
EU-1-21-1539,https://www.ema.europa.eu/documents/assessment-report/abecma-epar-public-assessment-report_en.pdf
EU-1-21-1540,https://www.ema.europa.eu/documents/assessment-report/dasatinib-accord-epar-public-assessment-report_en.pdf
EU-1-21-1541,https://www.ema.europa.eu/documents/assessment-report/dasatinib-accordpharma-epar-public-assessment-report_en.pdf
EU-1-19-1389,https://www.ema.europa.eu/documents/assessment-report/epidyolex-epar-public-assessment-report_en.pdf
EU-1-18-1284,https://www.ema.europa.eu/documents/assessment-report/dzuveo-epar-public-assessment-report_en.pdf
EU-1-19-1388,https://www.ema.europa.eu/documents/assessment-report/polivy-epar-public-assessment-report_en.pdf
EU-1-95-001,https://www.ema.europa.eu/documents/scientific-discussion/gonal-f-epar-scientific-discussion_en.pdf
EU-1-18-1302,https://www.ema.europa.eu/documents/assessment-report/kigabeq-epar-public-assessment-report_en.pdf
EU-1-19-1358,https://www.ema.europa.eu/documents/assessment-report/ajovy-epar-public-assessment-report_en.pdf
EU-1-19-1360,https://www.ema.europa.eu/documents/assessment-report/waylivra-epar-public-assessment-report_en.pdf
EU-1-19-1387,https://www.ema.europa.eu/documents/assessment-report/senstend-epar-public-assessment-report_en.pdf
EU-1-18-1290,https://www.ema.europa.eu/documents/assessment-report/nityr-epar-public-assessment-report_en.pdf
EU-1-18-1296,https://www.ema.europa.eu/documents/assessment-report/tegsedi-epar-public-assessment-report_en.pdf
EU-1-18-1297,https://www.ema.europa.eu/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf
EU-1-19-1353,https://www.ema.europa.eu/documents/assessment-report/atazanavir-krka-epar-public-assessment-report_en.pdf
EU-1-19-1354,https://www.ema.europa.eu/documents/assessment-report/vizimpro-epar-public-assessment-report_en.pdf
EU-1-19-1355,https://www.ema.europa.eu/documents/assessment-report/lorviqua-epar-public-assessment-report_en.pdf
EU-1-20-1477,https://www.ema.europa.eu/documents/assessment-report/fampridine-accord-epar-public-assessment-report_en.pdf
EU-1-20-1479,https://www.ema.europa.eu/documents/assessment-report/calquence-epar-public-assessment-report_en.pdf
EU-1-19-1359,https://www.ema.europa.eu/documents/assessment-report/trogarzo-epar-public-assessment-report_en.pdf
EU-1-18-1289,https://www.ema.europa.eu/documents/assessment-report/biktarvy-epar-public-assessment-report_en.pdf
EU-1-18-1294,https://www.ema.europa.eu/documents/assessment-report/rxulti-epar-public-assessment-report_en.pdf
EU-1-18-1299,https://www.ema.europa.eu/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf
EU-1-19-1399,https://www.ema.europa.eu/documents/assessment-report/xospata-epar-public-assessment-report_en.pdf
EU-1-19-1407,https://www.ema.europa.eu/documents/assessment-report/isturisa-epar-public-assessment-report_.pdf
EU-1-18-1287,https://www.ema.europa.eu/documents/assessment-report/hefiya-epar-public-assessment-report_en.pdf
EU-1-19-1369,https://www.ema.europa.eu/documents/assessment-report/sixmo-epar-public-assessment-report_en.pdf
EU-1-20-1457,https://www.ema.europa.eu/documents/assessment-report/xenleta-epar-public-assessment-report_en.pdf
EU-1-20-1458,https://www.ema.europa.eu/documents/assessment-report/apixaban-accord-epar-public-assessment-report_en.pdf
EU-1-19-1403,https://www.ema.europa.eu/documents/assessment-report/budesonide/formoterol-teva-pharma-bv-epar-public-assessment-report_en.pdf
EU-1-20-1478,https://www.ema.europa.eu/documents/assessment-report/zynrelef-epar-public-assessment-report_en.pdf
EU-1-18-1328,https://www.ema.europa.eu/documents/assessment-report/pelmeg-epar-public-assessment-report_en.pdf
EU-1-18-1329,https://www.ema.europa.eu/documents/assessment-report/fulphila-public-assessment-report_en.pdf
EU-1-18-1330,https://www.ema.europa.eu/documents/assessment-report/emgality-h-c-04648-x-0004-epar-refusal-public-assessment-report_en.pdf
EU-1-18-1351,https://www.ema.europa.eu/documents/assessment-report/trecondi-epar-public-assessment-report_en.pdf
EU-1-18-1352,https://www.ema.europa.eu/documents/assessment-report/besremi-epar-public-assessment-report_en.pdf
EU-1-20-1442,https://www.ema.europa.eu/documents/assessment-report/zeposia-epar-public-assessment-report_en.pdf
EU-1-20-1492,https://www.ema.europa.eu/documents/assessment-report/tecartus-epar-public-assessment-report_en.pdf
EU-1-20-1493,https://www.ema.europa.eu/documents/assessment-report/libmeldy-epar-public-assessment-report_en.pdf
EU-1-21-1535,https://www.ema.europa.eu/documents/assessment-report/pemazyre-epar-public-assessment-report_en.pdf
EU-1-21-1536,https://www.ema.europa.eu/documents/assessment-report/thiotepa-riemser-epar-public-assessment-report_en.pdf
EU-1-18-1312,https://www.ema.europa.eu/documents/assessment-report/xerava-epar-public-assessment-report_en.pdf
EU-1-18-1324,https://www.ema.europa.eu/documents/assessment-report/jivi-public-assessment-report_en.pdf
EU-1-19-1417,https://www.ema.europa.eu/documents/assessment-report/beovu-epar-public-assessment-report_en.pdf
EU-1-18-1348,https://www.ema.europa.eu/documents/assessment-report/lusutrombopag-shionogi-epar-public-assessment-report_en.pdf
EU-1-19-1418,https://www.ema.europa.eu/documents/assessment-report/dexmedetomidine-accord-epar-public-assessment-report_en.pdf
EU-1-18-1318,https://www.ema.europa.eu/documents/assessment-report/slenyto-epar-public-assessment-report_en.pdf
EU-1-18-1321,https://www.ema.europa.eu/documents/assessment-report/gefitinib-mylan-epar-public-assessment-report_en.pdf
EU-1-18-1344,https://www.ema.europa.eu/documents/assessment-report/zirabev-epar-public-assessment-report_en.pdf
EU-1-18-1345,https://www.ema.europa.eu/documents/assessment-report/ondexxya-epar-public-assessment-report_en.pdf
EU-1-20-1499,https://www.ema.europa.eu/documents/assessment-report/onbevzi-epar-public-assessment-report_en.pdf
EU-1-20-1496,https://www.ema.europa.eu/documents/assessment-report/oxlumo-epar-public-assessment-report_en.pdf
EU-1-20-1518,https://www.ema.europa.eu/documents/assessment-report/rukobia-epar-public-assessment-report_en.pdf
EU-1-18-1313,https://www.ema.europa.eu/documents/assessment-report/pelgraz-epar-public-assessment-report_en.pdf
EU-1-18-1331,https://www.ema.europa.eu/documents/assessment-report/luxturna-epar-public-assessment-report_en.pdf
EU-1-18-1332,https://www.ema.europa.eu/documents/assessment-report/pifeltro-epar-public-assessment-report_en.pdf
EU-1-18-1333,https://www.ema.europa.eu/documents/assessment-report/delstrigo-epar-public-assessment-report_en.pdf
EU-1-20-1424,https://www.ema.europa.eu/documents/assessment-report/nustendi-epar-public-assessment-report_en.pdf
EU-1-20-1425,https://www.ema.europa.eu/documents/assessment-report/nilemdo-epar-public-assessment-report_en.pdf
EU-1-20-1482,https://www.ema.europa.eu/documents/assessment-report/rekambys-epar-public-assessment-report_en.pdf
EU-1-18-1311,https://www.ema.europa.eu/documents/assessment-report/nerlynx-epar-public-assessment-report_en.pdf
EU-1-18-1293,https://www.ema.europa.eu/documents/assessment-report/aimovig-epar-public-assessment-report_en.pdf
EU-1-19-1380,https://www.ema.europa.eu/documents/assessment-report/posaconazole-ahcl-epar-public-assessment-report_en.pdf
EU-1-21-1538,https://www.ema.europa.eu/documents/assessment-report/jemperli-epar-public-assessment-report_en.pdf
EU-1-18-1325,https://www.ema.europa.eu/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf
EU-1-18-1326,https://www.ema.europa.eu/documents/assessment-report/flucelvax-tetra-epar-public-assessment-report_en.pdf
EU-1-18-1340,https://www.ema.europa.eu/documents/assessment-report/takhzyro-epar-public-assessment-report_en.pdf
EU-1-18-1341,https://www.ema.europa.eu/documents/assessment-report/ogivri-epar-public-assessment-report_en.pdf
EU-1-18-1306,https://www.ema.europa.eu/documents/assessment-report/symkevi-epar-public-assessment-report_en.pdf
EU-1-18-1307,https://www.ema.europa.eu/documents/assessment-report/verzenios-epar-public-assessment-report_en.pdf
EU-1-14-922,https://www.ema.europa.eu/documents/assessment-report/incruse-epar-public-assessment-report_en.pdf
EU-1-18-1349,https://www.ema.europa.eu/documents/assessment-report/dectova-epar-public-assessment-report_en.pdf
EU-1-20-1426,https://www.ema.europa.eu/documents/assessment-report/azacitidine-mylan-epar-public-assessment-report_en.pdf
EU-1-20-1427,https://www.ema.europa.eu/documents/assessment-report/arsenic-trioxide-mylan-epar-public-assessment-report_en.pdf
EU-1-16-1130,https://www.ema.europa.eu/documents/assessment-report/onivyde-epar-public-assessment-report_en.pdf
EU-1-96-011,https://www.ema.europa.eu/documents/scientific-discussion/caelyx-epar-scientific-discussion_en.pdf
EU-1-20-1515,https://www.ema.europa.eu/documents/assessment-report/abevmy-epar-public-assessment-report_en.pdf
EU-1-20-1488,https://www.ema.europa.eu/documents/assessment-report/rivaroxaban-accord-epar-public-assessment-report_en.pdf
EU-1-20-1490,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-mylan-epar-public-assessment-report_en.pdf
EU-1-20-1527,https://www.ema.europa.eu/documents/assessment-report/retsevmo-epar-public-assessment-report_en.pdf
EU-1-02-204,https://www.ema.europa.eu/documents/scientific-discussion/trisenox-epar-scientific-discussion_en.pdf
EU-1-19-1412,https://www.ema.europa.eu/documents/assessment-report/deferasirox-accord-epar-public-assessment-report_en.pdf
EU-1-20-1486,https://www.ema.europa.eu/documents/assessment-report/nyvepria-epar-public-assessment-report_en.pdf
EU-1-20-1487,https://www.ema.europa.eu/documents/assessment-report/phelinun-epar-public-assessment-report_en.pdf
EU-1-14-898,https://www.ema.europa.eu/documents/assessment-report/anoro-epar-public-assessment-report_en.pdf
EU-1-20-1497,https://www.ema.europa.eu/documents/assessment-report/phesgo-epar-public-assessment-report_en.pdf
EU-1-20-1495,https://www.ema.europa.eu/documents/assessment-report/palforzia-epar-public-assessment-report_en.pdf
EU-1-20-1524,https://www.ema.europa.eu/documents/assessment-report/vazkepa-epar-public-assessment-report_en.pdf
EU-1-18-1295,https://www.ema.europa.eu/documents/assessment-report/trazimera-epar-public-assessment-report_en.pdf
EU-1-17-1191,https://www.ema.europa.eu/documents/assessment-report/dinutuximab-beta-apeiron-epar-public-assessment-report_en.pdf
EU-1-20-1501,https://www.ema.europa.eu/documents/assessment-report/sogroya-epar-public-assessment-report_en.pdf
EU-1-18-1319,https://www.ema.europa.eu/documents/assessment-report/hulio-epar-public-assessment-report_en.pdf
EU-1-19-1413,https://www.ema.europa.eu/documents/assessment-report/azacitidine-accord-epar-public-assessment-report_en.pdf
EU-1-19-1416,https://www.ema.europa.eu/documents/assessment-report/azacitidine-betapharm-epar-public-assessment-report_.pdf
EU-1-20-1437,https://www.ema.europa.eu/documents/assessment-report/pretomanid-fgk-epar-public-assessment-report_en.pdf
EU-1-21-1533,https://www.ema.europa.eu/documents/assessment-report/seffalair-spiromax-epar-public-assessment-report_en.pdf
EU-1-21-1534,https://www.ema.europa.eu/documents/assessment-report/bropair-spiromax-epar-public-assessment-report_en.pdf
EU-1-21-1537,https://www.ema.europa.eu/documents/assessment-report/nexpovio-epar-public-assessment-report_en.pdf
EU-1-18-1314,https://www.ema.europa.eu/documents/assessment-report/braftovi-epar-public-assessment-report_en.pdf
EU-1-18-1315,https://www.ema.europa.eu/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf
EU-1-18-1316,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-accord-epar-public-assessment-report_en.pdf
EU-1-18-1338,https://www.ema.europa.eu/documents/assessment-report/dengvaxia-epar-public-assessment-report_en.pdf
EU-1-18-1342,https://www.ema.europa.eu/documents/assessment-report/erleada-epar-public-assessment-report_en.pdf
EU-1-20-1526,https://www.ema.europa.eu/documents/assessment-report/tukysa-epar-public-assessment-report_en.pdf
EU-1-19-1381,https://www.ema.europa.eu/documents/assessment-report/lysakare-epar-public-assessment-report_en.pdf
EU-1-19-1383,https://www.ema.europa.eu/documents/assessment-report/lacosamide-ucb-epar-public-assessment-report_en.pdf
EU-1-20-1438,https://www.ema.europa.eu/documents/assessment-report/enerzair-breezhaler-epar-public-assessment-report_en.pdf
EU-1-20-1439,https://www.ema.europa.eu/documents/assessment-report/atectura-breezhaler-epar-public-assessment-report_en.pdf
EU-1-20-1440,https://www.ema.europa.eu/documents/assessment-report/zimbus-breezhaler-epar-public-assessment-report_en.pdf
EU-1-20-1441,https://www.ema.europa.eu/documents/assessment-report/bemrist-breezhaler-epar-public-assessment-report_en.pdf
EU-1-18-1310,https://www.ema.europa.eu/documents/assessment-report/deferiprone-lipomed-epar-public-assessment-report_en.pdf
EU-1-18-1343,https://www.ema.europa.eu/documents/assessment-report/silodosin-recordati-epar-public-assessment-report_en.pdf
EU-1-19-1419,https://www.ema.europa.eu/documents/assessment-report/trepulmix-epar-public-assessment-report_en.pdf
EU-1-20-1423,https://www.ema.europa.eu/documents/assessment-report/vaxchora-epar-public-assessment-report_en.pdf
EU-1-20-1517,https://www.ema.europa.eu/documents/assessment-report/sibnayal-epar-public-assessment-report_en.pdf
EU-1-20-1528,https://www.ema.europa.eu/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
EU-1-18-1320,https://www.ema.europa.eu/documents/assessment-report/onpattro-epar-public-assessment-report_.pdf
EU-1-20-1429,https://www.ema.europa.eu/documents/assessment-report/cinacalcet-accordpharma-epar-public-assessment-report_en.pdf
EU-1-20-1430,https://www.ema.europa.eu/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf
EU-1-20-1433,https://www.ema.europa.eu/documents/assessment-report/fluad-tetra-epar-public-assessment-report_en.pdf
EU-1-20-1502,https://www.ema.europa.eu/documents/assessment-report/roclanda-epar-public-assessment-report_en.pdf
EU-1-20-1504,https://www.ema.europa.eu/documents/assessment-report/elzonris-epar-public-assessment-report_en.pdf
EU-1-18-1335,https://www.ema.europa.eu/documents/assessment-report/poteligeo-epar-public-assessment-report_en.pdf
EU-1-20-1503,https://www.ema.europa.eu/documents/assessment-report/heplisav-b-epar-public-assessment-report_en.pdf
EU-1-18-1286,https://www.ema.europa.eu/documents/assessment-report/hyrimoz-epar-public-assessment-report_en.pdf
EU-1-20-1498,https://www.ema.europa.eu/documents/assessment-report/trixeo-aerosphere-epar-public-assessment-report_en.pdf
EU-1-16-1139,https://www.ema.europa.eu/documents/assessment-report/ocaliva-epar-public-assessment-report_en.pdf
EU-1-20-1435,https://www.ema.europa.eu/documents/assessment-report/sarclisa-epar-public-assessment-report_en-0.pdf
EU-1-18-1322,https://www.ema.europa.eu/documents/assessment-report/imfinzi-epar-public-assessment-report_en.pdf
EU-1-20-1446,https://www.ema.europa.eu/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf
EU-1-20-1505,https://www.ema.europa.eu/documents/assessment-report/byfavo-epar-public-assessment-report_en.pdf
EU-1-20-1508,https://www.ema.europa.eu/documents/assessment-report/enhertu-epar-public-assessment-report_en.pdf
EU-1-20-1509,https://www.ema.europa.eu/documents/assessment-report/alymsys-epar-public-assessment-report_en.pdf
EU-1-20-1510,https://www.ema.europa.eu/documents/assessment-report/oyavas-epar-public-assessment-report_en.pdf
EU-1-20-1511,https://www.ema.europa.eu/documents/assessment-report/sunitinib-accord-epar-public-assessment-report_en.pdf
EU-1-20-1512,https://www.ema.europa.eu/documents/assessment-report/abiraterone-accord-epar-public-assessment-report_en.pdf
EU-1-18-1323,https://www.ema.europa.eu/documents/assessment-report/ilumetri-epar-public-assessment-report_en.pdf
EU-1-00-141,https://www.ema.europa.eu/documents/scientific-discussion/myocet-epar-scientific-discussion_en.pdf
EU-1-21-1530,https://www.ema.europa.eu/documents/assessment-report/ontozry-epar-public-assessment-report_.pdf
EU-1-18-1339,https://www.ema.europa.eu/documents/assessment-report/bevespi-aerosphere-epar-public-assessment-report_en.pdf
EU-1-20-1489,https://www.ema.europa.eu/documents/assessment-report/exparel-liposomal-epar-public-assessment-report_en.pdf
EU-1-20-1521,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-krka-dd-epar-public-assessment-report_en.pdf
EU-1-20-1523,https://www.ema.europa.eu/documents/assessment-report/ogluo-epar-public-assessment-report_en.pdf
EU-1-18-1346,https://www.ema.europa.eu/documents/assessment-report/miglustat-dipharma-epar-public-assessment-report_en.pdf
EU-1-19-1384,https://www.ema.europa.eu/documents/assessment-report/giapreza-epar-public-assessment-report_en.pdf
EU-1-19-1421,https://www.ema.europa.eu/documents/assessment-report/staquis-epar-public-assessment-report_en.pdf
EU-1-20-1422,https://www.ema.europa.eu/documents/assessment-report/liumjev-epar-public-assessment-report_en.pdf
EU-1-18-1301,https://www.ema.europa.eu/documents/assessment-report/mepsevii-epar-public-assessment-report_en.pdf
EU-1-20-1513,https://www.ema.europa.eu/documents/assessment-report/yuflyma-epar-public-assessment-report_en.pdf
EU-1-18-1327,https://www.ema.europa.eu/documents/assessment-report/ziextenzo-epar-public-assessment-report_en.pdf
EU-1-20-1436,https://www.ema.europa.eu/documents/assessment-report/nepexto-epar-public-assessment-report_en.pdf
EU-1-20-1491,https://www.ema.europa.eu/documents/assessment-report/fintepla-epar-public-assessment-report_en.pdf
EU-1-19-1414,https://www.ema.europa.eu/documents/assessment-report/mayzent-epar-public-assessment-report_en.pdf
EU-1-20-1500,https://www.ema.europa.eu/documents/assessment-report/xofluza-epar-public-assessment-report_en.pdf
EU-1-20-1514,https://www.ema.europa.eu/documents/assessment-report/inrebic-epar-public-assessment-report_en.pdf
EU-1-19-1415,https://www.ema.europa.eu/documents/assessment-report/amsparity-epar-public-assessment-report_en.pdf
EU-1-18-1305,https://www.ema.europa.eu/documents/assessment-report/cablivi-epar-public-assessment-report_en.pdf
EU-1-18-1317,https://www.ema.europa.eu/documents/assessment-report/pazenir-epar-public-assessment-report_en.pdf
EU-1-18-1347,https://www.ema.europa.eu/documents/assessment-report/febuxostat-krka-epar-public-assessment-report_en.pdf
EU-1-20-1483,https://www.ema.europa.eu/documents/assessment-report/menquadfi-epar-public-assessment-report_en.pdf
EU-1-20-1484,https://www.ema.europa.eu/documents/assessment-report/supemtek-epar-public-assessment-report_en.pdf
EU-1-20-1485,https://www.ema.europa.eu/documents/assessment-report/obiltoxaximab-sfl-epar-public-assessment-report_en.pdf
EU-1-20-1470,https://www.ema.europa.eu/documents/assessment-report/methylthioninium-chloride-cosmo-epar-public-assessment-report_en.pdf
EU-1-21-1531,https://www.ema.europa.eu/documents/assessment-report/evrysdi-epar-public-assessment-report_en.pdf
EU-1-21-1532,https://www.ema.europa.eu/documents/assessment-report/kesimpta-epar-public-assessment-report_en.pdf
EU-1-18-1336,https://www.ema.europa.eu/documents/assessment-report/buvidal-epar-public-assessment-report_en.pdf
EU-1-11-696,https://www.ema.europa.eu/documents/assessment-report/bydureon-epar-public-assessment-report_en.pdf
EU-1-20-1428,https://www.ema.europa.eu/documents/assessment-report/givlaari-epar-public-assessment-report_en.pdf
EU-1-20-1481,https://www.ema.europa.eu/documents/assessment-report/vocabria-epar-public-assessment-report_en.pdf
EU-1-18-1308,https://www.ema.europa.eu/documents/assessment-report/vyxeos-epar-public-assessment-report_en.pdf
EU-1-19-1420,https://www.ema.europa.eu/documents/assessment-report/recarbrio-epar-public-assessment-report_en.pdf
EU-1-20-1431,https://www.ema.europa.eu/documents/assessment-report/ruxience-epar-public-assessment-report_en.pdf
EU-1-20-1434,https://www.ema.europa.eu/documents/assessment-report/fetcroja-epar-public-assessment-report_en.pdf
EU-1-20-1444,https://www.ema.europa.eu/documents/assessment-report/zabdeno-epar-public-assessment-report_en.pdf
EU-1-20-1445,https://www.ema.europa.eu/documents/assessment-report/mvabea-epar-public-assessment-report_en.pdf
EU-1-20-1432,https://www.ema.europa.eu/documents/assessment-report/nubeqa-epar-public-assessment-report_en.pdf
EU-1-20-1443,https://www.ema.europa.eu/documents/assessment-report/zolgensma-epar-public-assessment-report_en.pdf
EU-1-20-1494,https://www.ema.europa.eu/documents/assessment-report/leqvio-epar-public-assessment-report_en.pdf
EU-1-18-1291,https://www.ema.europa.eu/documents/assessment-report/rizmoic-epar-public-assessment-report_en.pdf
EU-1-21-1589,https://www.ema.europa.eu/documents/assessment-report/hukyndra-epar-public-assessment-report_en.pdf
EU-1-21-1590,https://www.ema.europa.eu/documents/assessment-report/libmyris-epar-public-assessment-report_en.pdf
EU-1-22-1644,https://www.ema.europa.eu/documents/assessment-report/inpremzia-epar-public-assessment-report_en.pdf
EU-1-08-443,https://www.ema.europa.eu/documents/assessment-report/thalidomide-celgene-epar-public-assessment-report_en.pdf
EU-1-21-1561,https://www.ema.europa.eu/documents/assessment-report/verquvo-epar-public-assessment-report_en.pdf
EU-1-21-1588,https://www.ema.europa.eu/documents/assessment-report/rivaroxaban-mylan-epar-public-assessment-report_en.pdf
EU-1-20-1519,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-krka-dd-novo-mesto-epar-public-assessment-report_en.pdf
EU-1-20-1520,https://www.ema.europa.eu/documents/assessment-report/lenalidomide-krka-epar-public-assessment-report_en.pdf
EU-1-21-1597,https://www.ema.europa.eu/documents/assessment-report/regkirona-epar-public-assessment-report_en.pdf
EU-1-21-1598,https://www.ema.europa.eu/documents/assessment-report/sitagliptin-sun-epar-public-assessment-report_en.pdf
EU-1-21-1612,https://www.ema.europa.eu/documents/assessment-report/apexxnar-epar-public-assessment-report_en.pdf
EU-1-21-1542,https://www.ema.europa.eu/documents/assessment-report/copiktra-epar-public-assessment-report_en.pdf
EU-1-21-1547,https://www.ema.europa.eu/documents/assessment-report/drovelis-epar-public-assessment-report_en.pdf
EU-1-21-1548,https://www.ema.europa.eu/documents/assessment-report/lydisilka-epar-public-assessment-report_en.pdf
EU-1-21-1593,https://www.ema.europa.eu/documents/assessment-report/cibinqo-epar-public-assessment-report_en.pdf
EU-1-21-1594,https://www.ema.europa.eu/documents/assessment-report/rybrevant-epar-public-assessment-report_en.pdf
EU-1-21-1600,https://www.ema.europa.eu/documents/assessment-report/tecovirimat-siga-epar-public-assessment-report_en.pdf
EU-1-21-1608,https://www.ema.europa.eu/documents/assessment-report/wegovy-epar-public-assessment-report_en.pdf
EU-1-21-1546,https://www.ema.europa.eu/documents/assessment-report/ozawade-epar-public-assessment-report_en.pdf
EU-1-21-1550,https://www.ema.europa.eu/documents/assessment-report/ponvory-epar-public-assessment-report_en.pdf
EU-1-21-1596,https://www.ema.europa.eu/documents/assessment-report/tepmetko-epar-public-assessment-report_en.pdf
EU-1-03-271,https://www.ema.europa.eu/documents/scientific-discussion/advate-epar-scientific-discussion_en.pdf
EU-1-21-1555,https://www.ema.europa.eu/documents/assessment-report/gavreto-epar-public-assessment-report_en.pdf
EU-1-21-1556,https://www.ema.europa.eu/documents/assessment-report/onureg-epar-public-assessment-report_en.pdf
EU-1-21-1576,https://www.ema.europa.eu/documents/assessment-report/brukinsa-epar-public-assessment-report_en.pdf
EU-1-21-1601,https://www.ema.europa.eu/documents/assessment-report/ronapreve-epar-public-assessment-report_en.pdf
EU-1-21-1602,https://www.ema.europa.eu/documents/assessment-report/uplizna-epar-public-assessment-report_en.pdf
EU-1-21-1591,https://www.ema.europa.eu/documents/assessment-report/vaxneuvance-epar-public-assessment-report_en.pdf
EU-1-21-1606,https://www.ema.europa.eu/documents/assessment-report/yselty-epar-public-assessment-report_en.pdf
EU-1-21-1607,https://www.ema.europa.eu/documents/assessment-report/lonapegsomatropin-ascendis-pharma-epar-public-assessment-report_en.pdf
EU-1-22-1634,https://www.ema.europa.eu/documents/assessment-report/dimethyl-fumarate-mylan-epar-public-assessment-report_en.pdf
EU-1-22-1635,https://www.ema.europa.eu/documents/assessment-report/dimethyl-fumarate-polpharma-epar-public-assessment-report_en.pdf
EU-1-22-1637,https://www.ema.europa.eu/documents/assessment-report/dimethyl-fumarate-neuraxpharm-epar-public-assessment-report_en.pdf
EU-1-22-1638,https://www.ema.europa.eu/documents/assessment-report/quviviq-epar-public-assessment-report_en.pdf
EU-1-22-1645,https://www.ema.europa.eu/documents/assessment-report/vydura-epar-public-assessment-report_en.pdf
EU-1-21-1553,https://www.ema.europa.eu/documents/assessment-report/abiraterone-krka-epar-public-assessment-report_en.pdf
EU-1-17-1189,https://www.ema.europa.eu/documents/assessment-report/elmiron-epar-public-assessment-report_en.pdf
EU-1-21-1604,https://www.ema.europa.eu/documents/assessment-report/riltrava-aerosphere-epar-public-assessment-report_en.pdf
EU-1-21-1605,https://www.ema.europa.eu/documents/assessment-report/tavneos-epar-public-assessment-report_en.pdf
EU-1-21-1618,https://www.ema.europa.eu/documents/assessment-report/nuvaxovid-epar-public-assessment-report_en.pdf
EU-1-21-1573,https://www.ema.europa.eu/documents/assessment-report/fingolimod-mylan-epar-public-assessment-report_en.pdf
EU-1-21-1615,https://www.ema.europa.eu/documents/assessment-report/padcev-epar-public-assessment-report_en.pdf
EU-1-21-1616,https://www.ema.europa.eu/documents/assessment-report/kerendia-epar-public-assessment-report_en.pdf
EU-1-21-1617,https://www.ema.europa.eu/documents/assessment-report/ngenla-epar-public-assessment-report_en.pdf
EU-1-21-1622,https://www.ema.europa.eu/documents/assessment-report/oxbryta-epar-public-assessment-report_en.pdf
EU-1-22-1663,https://www.ema.europa.eu/documents/assessment-report/sugammadex-fresenius-kabi-epar-public-assessment-report_en.pdf
EU-1-21-1552,https://www.ema.europa.eu/documents/assessment-report/koselugo-epar-public-assessment-report_en.pdf
EU-1-21-1568,https://www.ema.europa.eu/documents/assessment-report/imatinib-koanaa-epar-public-assessment-report_en.pdf
EU-1-21-1569,https://www.ema.europa.eu/documents/assessment-report/qinlock-epar-public-assessment-report_en.pdf
EU-1-21-1572,https://www.ema.europa.eu/documents/assessment-report/byooviz-epar-public-assessment-report_en.pdf
EU-1-21-1599,https://www.ema.europa.eu/documents/assessment-report/vyepti-epar-public-assessment-report_en.pdf
EU-1-18-1337,https://www.ema.europa.eu/documents/assessment-report/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf
EU-1-21-1624,https://www.ema.europa.eu/documents/assessment-report/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-public-assessment-report_en.pdf
EU-1-21-1574,https://www.ema.europa.eu/documents/assessment-report/evrenzo-epar-public-assessment-report_en.pdf
EU-1-21-1577,https://www.ema.europa.eu/documents/assessment-report/voxzogo-epar-public-assessment-report_en.pdf
EU-1-21-1623,https://www.ema.europa.eu/documents/assessment-report/saphnelo-epar-public-assessment-report_en.pdf
EU-1-22-1631,https://www.ema.europa.eu/documents/assessment-report/breyanzi-epar-public-assessment-report_en.pdf
EU-1-22-1632,https://www.ema.europa.eu/documents/assessment-report/stimufend-epar-public-assessment-report_en.pdf
EU-1-22-1633,https://www.ema.europa.eu/documents/assessment-report/sitagliptin-accord-epar-public-assessment-report_en.pdf
EU-1-22-1639,https://www.ema.europa.eu/documents/assessment-report/truvelog-mix-30-epar-public-assessment-report_en.pdf
EU-1-22-1640,https://www.ema.europa.eu/documents/assessment-report/amversio-epar-public-assessment-report_en.pdf
EU-1-21-1583,https://www.ema.europa.eu/documents/assessment-report/sugammadex-mylan-epar-public-assessment-report_en.pdf
EU-1-20-1453,https://www.ema.europa.eu/documents/assessment-report/paliperidone-janssen-cilag-international-epar-public-assessment-report_en.pdf
EU-1-21-1603,https://www.ema.europa.eu/documents/assessment-report/lumykras-epar-public-assessment-report_en.pdf
EU-1-21-1621,https://www.ema.europa.eu/documents/assessment-report/okedi-epar-public-assessment-report_en.pdf
EU-1-22-1641,https://www.ema.europa.eu/documents/assessment-report/prehevbri-epar-public-assessment-report_en.pdf
EU-1-22-1642,https://www.ema.europa.eu/documents/assessment-report/orgovyx-epar-public-assessment-report_en.pdf
EU-1-20-1507,https://www.ema.europa.eu/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf
EU-1-22-1643,https://www.ema.europa.eu/documents/assessment-report/kapruvia-epar-public-assessment-report_en.pdf
EU-1-21-1570,https://www.ema.europa.eu/documents/assessment-report/minjuvi-epar-public-assessment-report_en.pdf
EU-1-21-1571,https://www.ema.europa.eu/documents/assessment-report/abiraterone-mylan-epar-public-assessment-report_en.pdf
EU-1-22-1669,https://www.ema.europa.eu/documents/assessment-report/pepaxti-epar-public-assessment-report_en.pdf
EU-1-21-1611,https://www.ema.europa.eu/documents/assessment-report/vildagliptin/metformin-hydrochloride-accord-epar-public-assessment-report_en.pdf
EU-1-22-1652,https://www.ema.europa.eu/documents/assessment-report/filsuvez-epar-public-assessment-report_en.pdf
EU-1-22-1653,https://www.ema.europa.eu/documents/assessment-report/upstaza-epar-public-assessment-report_en.pdf
EU-1-07-437,https://www.ema.europa.eu/documents/assessment-report/ivemend-epar-public-assessment-report_en.pdf
EU-1-22-1658,https://www.ema.europa.eu/documents/assessment-report/ganirelix-gedeon-richter-epar-public-assessment-report_en.pdf
EU-1-21-1582,https://www.ema.europa.eu/documents/assessment-report/artesunate-amivas-epar-public-assessment-report_en.pdf
EU-1-21-1592,https://www.ema.europa.eu/documents/assessment-report/trodelvy-epar-public-assessment-report_en.pdf
EU-1-21-1549,https://www.ema.europa.eu/documents/assessment-report/efmody-epar-public-assessment-report_en.pdf
EU-1-21-1564,https://www.ema.europa.eu/documents/assessment-report/imcivree-epar-public-assessment-report_en.pdf
EU-1-21-1575,https://www.ema.europa.eu/documents/assessment-report/bimzelx-epar-public-assessment-report_en.pdf
EU-1-22-1629,https://www.ema.europa.eu/documents/assessment-report/zolsketil-pegylated-liposomal-epar-public-assessment-report_en.pdf
EU-1-22-1630,https://www.ema.europa.eu/documents/assessment-report/kimmtrak-epar-public-assessment-report_en.pdf
EU-1-22-1651,https://www.ema.europa.eu/documents/assessment-report/evusheld-epar-public-assessment-report_en.pdf
EU-1-21-1595,https://www.ema.europa.eu/documents/assessment-report/aspaveli-epar-public-assessment-report_en.pdf
EU-1-21-1619,https://www.ema.europa.eu/documents/assessment-report/sitagliptin/metformin-hydrochloride-mylan-epar-public-assessment-report_en.pdf
EU-1-21-1620,https://www.ema.europa.eu/documents/assessment-report/sapropterin-dipharma-epar-public-assessment-report_en.pdf
EU-1-21-1544,https://www.ema.europa.eu/documents/assessment-report/orladeyo-epar-public-assessment-report_en.pdf
EU-1-21-1578,https://www.ema.europa.eu/documents/assessment-report/ontilyv-epar-public-assessment-report_en.pdf
EU-1-09-568,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-mylan-pharma-epar-public-assessment-report_en.pdf
EU-1-09-559,https://www.ema.europa.eu/documents/assessment-report/clopidogrel-mylan-epar-public-assessment-report_en.pdf
EU-1-22-1646,https://www.ema.europa.eu/documents/assessment-report/amifampridine-serb-epar-public-assessment-report_en.pdf
EU-1-20-1525,https://www.ema.europa.eu/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf
EU-1-21-1565,https://www.ema.europa.eu/documents/assessment-report/ryeqo-epar-public-assessment-report_en.pdf
EU-1-21-1529,https://www.ema.europa.eu/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf
EU-1-22-1625,https://www.ema.europa.eu/documents/assessment-report/paxlovid-epar-public-assessment-report_en.pdf
EU-1-22-1657,https://www.ema.europa.eu/documents/assessment-report/kinpeygo-epar-public-assessment-report_en.pdf
EU-1-21-1559,https://www.ema.europa.eu/documents/assessment-report/enspryng-epar-public-assessment-report_en.pdf
EU-1-21-1560,https://www.ema.europa.eu/documents/assessment-report/celsunax-epar-public-assessment-report_en.pdf
EU-1-21-1579,https://www.ema.europa.eu/documents/assessment-report/nexviadyme-epar-public-assessment-report_en.pdf
EU-1-22-1628,https://www.ema.europa.eu/documents/assessment-report/sondelbay-epar-public-assessment-report_en.pdf
EU-1-22-1659,https://www.ema.europa.eu/documents/assessment-report/xenpozyme-epar-public-assessment-report_en.pdf
EU-1-22-1660,https://www.ema.europa.eu/documents/assessment-report/zokinvy-epar-public-assessment-report_en.pdf
EU-1-22-1661,https://www.ema.europa.eu/documents/assessment-report/sitagliptin/metformin-hydrochloride-accord-epar-public-assessment-report_en.pdf
EU-1-18-1350,https://www.ema.europa.eu/documents/assessment-report/vantobra-previously-tobramycin-pari-epar-public-assessment-report_en.pdf
EU-1-21-1562,https://www.ema.europa.eu/documents/assessment-report/xevudy-epar-public-assessment-report_en.pdf
EU-1-15-1035,https://www.ema.europa.eu/documents/assessment-report/obizur-epar-public-assessment-report_en.pdf
EU-1-21-1585,https://www.ema.europa.eu/documents/assessment-report/vumerity-epar-public-assessment-report_en.pdf
EU-1-21-1586,https://www.ema.europa.eu/documents/assessment-report/voraxaze-epar-public-assessment-report_en.pdf
EU-1-22-1648,https://www.ema.europa.eu/documents/assessment-report/carvykti-epar-public-assessment-report_en.pdf
EU-1-21-1566,https://www.ema.europa.eu/documents/assessment-report/bylvay-epar-public-assessment-report_en.pdf
EU-1-22-1649,https://www.ema.europa.eu/documents/assessment-report/lunsumio-epar-public-assessment-report_en.pdf
EU-1-21-1567,https://www.ema.europa.eu/documents/assessment-report/icatibant-accord-epar-public-assessment-report_en.pdf
EU-1-22-1647,https://www.ema.europa.eu/documents/assessment-report/camcevi-epar-public-assessment-report_en.pdf
EU-1-20-1506,https://www.ema.europa.eu/documents/assessment-report/kixelle-epar-public-assessment-report_en.pdf
EU-1-15-1057,https://www.ema.europa.eu/documents/assessment-report/pemetrexed-hospira-epar-public-assessment-report_en.pdf
EU-1-22-1655,https://www.ema.europa.eu/documents/assessment-report/pirfenidone-aet-epar-public-assessment-report_en.pdf
EU-1-22-1671,https://www.ema.europa.eu/documents/assessment-report/sunlenca-epar-public-assessment-report_en.pdf
EU-1-07-435,https://www.ema.europa.eu/documents/assessment-report/tesavel-epar-public-assessment-report_en.pdf
